AU2019210414A1 - Pyridone derivative, composition thereof and application thereof as anti-influenza drug - Google Patents
Pyridone derivative, composition thereof and application thereof as anti-influenza drug Download PDFInfo
- Publication number
- AU2019210414A1 AU2019210414A1 AU2019210414A AU2019210414A AU2019210414A1 AU 2019210414 A1 AU2019210414 A1 AU 2019210414A1 AU 2019210414 A AU2019210414 A AU 2019210414A AU 2019210414 A AU2019210414 A AU 2019210414A AU 2019210414 A1 AU2019210414 A1 AU 2019210414A1
- Authority
- AU
- Australia
- Prior art keywords
- ring
- oho0
- carbonyl
- hydrocarbyl
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
Abstract
The present invention relates to the field of medical chemistry, and relates to a novel pyridone derivative represented by formula (I) or a stereoisomer thereof, a pharmaceutically acceptable salt, a solvate or a crystal thereof, and an application thereof in the preparation of a drug for preventing or treating viral infectious diseases such as influenza A or/and influenza B, in particular an application thereof as a PA subunit cap-dependent endonuclease inhibitor for preventing or treating influenza A and/or influenza B viral infectious diseases. The compound of the present invention has significant activity in inhibiting influenza endonuclease and influenza DNA, and may be used alone or in combination with a neuraminidase inhibitor, a nucleoside drug, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs, significantly shortening the time of influenza infection, reducing mortality, and having excellent clinical application prospects.
Description
Technical Field of the Invention The present disclosure belongs to the field of medicinal chemistry, and specifically relates to a novel pyridone derivative or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof, to a pharmaceutical composition containing the foregoing pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof, and to use thereof as an antiviral drug, in particular, use thereof in the preparation of a drug as a cap-dependent endonuclease inhibitor for preventing and/or treating influenza infection, in particular, such as use thereof in the preparation of a drug for preventing and/or treating influenza type A viral infection and/or influenza type B viral infection.
Background of the Invention The influenza is an acute respiratory infection caused by an influenza virus. Every year, influenza can cause thousands of deaths, and large-scale influenza outbreaks can cause millions of deaths worldwide. Although influenza vaccines and antiviral drugs such as amantadine can be used to prevent and treat influenza, their prevention and efficacy are very limited, and it is required to develop a broader spectrum of vaccine and more effective anti-influenza drug.
The neuraminidase inhibitors Oseltamivir and Zanamivir can suppress viral budding and release, but clinically the efficacy of neuraminidase inhibitors in critically ill patients is doubtful, and the widespread resistance is also a problem of neuraminidase inhibitors that must be considered. Due to the fear of a highly lethal new influenza pandemic, a new mechanism of anti-influenza drugs is urgently needed in the clinic.
The transcription of 8 RNA fragments is a critical step in the life course of influenza viruses. RNA polymerase plays a key role in this step. RNA polymerase is a trimer composed of three subunits PA, PB1 and PB2, which is responsible for the replication and transcription of viral RNA in the nuclei of infected host cells. The transcription of influenza virus RNA has a special "cap snatching" mechanism, the PB2 subunit is responsible for recognizing and binding to the "cap structure" of the host precursor mRNA, and the PA subunit cleaves the host mRNA as a primer to initiate the transcription process. The cleaved mRNA primers are used in the PB1 subunit for the synthesis of viral mRNA. Because the cap-dependent endonuclease of the PA subunit is very conservative during influenza variation and is necessary for viral life courses, and the binding site is specific, the binding domain is well suited as a target to develop new anti-influenza drugs. Since the endonuclease binding sites of influenza type A and influenza type B are very similar, cap-dependent endonuclease inhibitors have activity against both influenza type A and influenza type B viruses. The marketed influenza treatment drug Baloxavir marboxil is a cap-dependent endonuclease inhibitor that has a clinically highly effective therapeutic effect on type A/B influenza. CN102803260A discloses a substituted polycyclic carbamoylpyridone derivative which has an inhibitory activity against a cap-dependent endonuclease and can be used as a therapeutic and/or preventive agent for influenza infectious diseases.
Summary of the Invention
One of the purposes of the present disclosure is to provide a novel pyridone
derivative which can be used as a cap-dependent endonuclease inhibitor and which
is superior to the exsiting pyridone derivatives in at least one aspect of activity,
pharmacokinetic properties such as bioavailability and cytotoxicity.
A second purpose of the present disclosure is to provide a pyridone derivative
which not only has excellent cap-dependent endonuclease inhibitory activity and low cytotoxicity, but also has significantly improved pharmacokinetic properties, particularly bioavailability.
To achieve the above purposes, the present disclosure employs the following technical solutions: A pyridone derivative represented by Formula (I) or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof, W 00
O NRe AM N,
Ar2 7 (R7 )M
(I) wherein: (1) A is selected from N or CR1 , R1 is selected from hydrogen, cyano, hydroxy, halogen, carboxyl, ester, amide,sulfonyl amide; or, R1 is selected from the following unsubstituted or substituted groups: C 16. hydrocarbyl, C 1 .6 hydrocarbyloxy, C 1 .6 hydrocarbylamino, C 1 .6 hydrocarbylsulfydryl, carbonyl hydrazide, C 1 .6 hydrocarbyl carbonyl, C 1 .6 hydrocarbylamino carbonyl, C 1 .6
hydrocarbylcarbonyl amino, C1.6 hydrocarbyloxy carbonyl, C1.6 hydrocarbylsulfinyl, C 1 .6 hydrocarbylamino carbonylamino, C 3 6. cycloalkyl, C 3 .6 cycloalkoxy, C 3 .6 cycloalkylamino, C 3 .6 cycloalkylsulfydryl, C 3 .6 cycloalkylcarbonyl, C 3 -6cycloalkylamino carbonyl, C 3 -6cycloalkylcarbonyl amino, C 3 .6 cycloalkylamino carbonylamino, C 4 8. heterocycloalkyl, C 4 8.
heterocycloalkoxy, C 4 .8 heterocycloalkylamino, C 4 .8 heterocycloalkyl
sulfydryl, C 4 .8 heterocycloalkyl carbonyl, C 48. heterocycloalkylamino
carbonyl, C5 . 10 aryl, C5 .10 aryloxy, C5 1 0 aryloxy hydrocarbyl, C 5 . 10 arylamino,
C 5 . 1 0 aryl sulfydryl, C 5 .1 0 aryl carbonyl, C 1-6hydrocarbyl sulfonyl, C 1 .6
hydrocarbyl sulfonylamino,C 3 .6 cycloalkyl sulfonyl,C 3.6 cycloalkyl sulfonylamino,C 5 .10 aryl sulfonyl,C5 .10 aryl sulfonylamino, aminooxalyl amino, aminooxalyl,C 5.1 0 arylamino carbonyl orC 51 0 arylamino carbonylamino; (2) M is selected from N or CR2, R2 is selected from hydrogen, cyano, hydroxy, halogen, carboxyl, ester, amide,sulfonyl amide; or, R2 is selected from the following unsubstituted or substituted groups: C1 6. hydrocarbyl,C 1.6 hydrocarbyloxy,C1. 6 hydrocarbylamino,C 16. hydrocarbylsulfydryl, carbonyl hydrazide,C 1 .6 hydrocarbyl carbonyl,C 1.6 hydrocarbylamino carbonyl,C 1.6 hydrocarbylcarbonyl amino,CI 6 hydrocarbyloxy carbonyl,CI 6
hydrocarbylsulfinyl,C 1.6 hydrocarbylamino carbonylamino,C 3.6 cycloalkyl, C 3 .6 cycloalkoxy,C 3.6 cycloalkylamino,C 3.6 cycloalkylsulfydryl, C 3 .6 cycloalkylcarbonyl,C 3.6 cycloalkylamino carbonyl,C 3 .6 cycloalkylcarbonyl amino, C 3 .6 cycloalkylamino carbonylamino,C 48. heterocycloalkyl,C 48. heterocycloalkoxy,C 4.8 heterocycloalkylamino,C 4.8 heterocycloalkyl sulfydryl,C 4.8 heterocycloalkyl carbonyl,C 48. heterocycloalkylamino carbonyl,C 5 .10 aryl, C5 .10 aryloxy, C5 1 0 aryloxy hydrocarbyl,C 5.10 arylamino, C 5 . 1 0 aryl sulfydryl,C 5.10 aryl carbonyl,C 1 .6 hydrocarbyl sulfonyl,C 1 .6 hydrocarbyl sulfonylamino,C 3 .6 cycloalkyl sulfonyl,C 3.6 cycloalkyl sulfonylamino,C 5 .10 aryl sulfonyl,C 5.10 aryl sulfonylamino, aminooxalyl amino, aminooxalyl,C 5.1 0 arylamino carbonyl orC 51. 0 arylamino carbonylamino; or, R 1 and R 2 are connected and form a first ring together with carbon atoms connected therewith, or R 2 and R 7 are connected and form a second ring together with carbon atoms connected therewith; (3) Q is selected from N or CR 3, R3 is selected from hydrogen, cyano, carboxyl, ester,amide; or, R 3 is selected from the following unsubstituted or substituted groups: C1 -6hydrocarbyl,C 3.6 cycloalkyl,C 4.8 heterocycloalkyl, C 5. 10 aryl, C 3 .6 cycloalkyl sulfydryl, spirocyclic ring, bridged cyclic ring,C 36. cycloalkyl sulfydrylC 1.6 hydrocarbyl,C 3.6 cycloalkylC1 .6 hydrocarby
sulfydrylC 1 .6 hydrocarbyl,C 3.6 cycloalkylC1 .6 hydrocarbyl sulfydryl cycloalkyl,C 3.6 cycloalkyloxy cycloalkyl, cycloamideC1 6. hydrocarbyl, cycloamide cycloalkyl, cyclosulfonylCI 6 hydrocarbyl, cyclosulfonyl cycloalkyl; or, R 3 and R 4 are connected and form a third ring together with carbon atoms connected therewith; (4) R is selected from NH, carbonyl or CR4R, R 4 and Rare independently selected from hydrogen, cyano, carboxyl, ester,amide; or, R 4 and R5 are independently selected from the following unsubstituted or substituted groups: C1 .6 hydrocarbyl,C 1.6 hydrocarbyloxy,C 1.6 hydrocarbylamino,C 1.6 hydrocarbylsulfydryl,C 1 .6 hydrocarbylcarbonyl,CI 6 hydrocarbylamino carbonyl,C 1.6 hydrocarbylcarbonyl amino,C1. 6 hydrocarbyloxy carbonyl, C 1 .6 hydrocarbylamino acylamino,C 3.6 cycloalkyl,C 3.6 cycloalkoxy,C 36. cycloalkylamino,C 3.6 cycloalkylsulfydryl,C 3.6 cycloalkylcarbonyl,C 3.6 cycloalkylamino carbonyl,C 3 .6 cycloalkylamino carbonylamino,C 3.6 cycloalkylcarbonyl amino,C 4 .8 heterocycloalkyl, C 4 .8 heterocycloalkoxy, C 4 .8
heterocycloalkylamino,C 4 .8 heterocycloalkyl sulfydryl, C 4 8. heterocycloalkyl
carbonyl, C 4 .8 heterocycloalkylamino carbonyl, C 5 . 10 aryl, C 5 .10 aryloxy, C 5 .10
aryloxy C 1 .6 hydrocarbyl, C 5 .10 arylamino, C 5 .1 0 aryl sulfydryl, C 5 .10 aryl
carbonyl, C 5 .1 0 arylamino carbonyl or C 5 .1 0 arylamino carbonylamino; or, R4
and R 5 are connected and form a fourth ring together with carbon atoms
connected therewith;
(5) R 6 is selected from hydrogen or the following unsubstituted or substituted
groups: C 1 .6 hydrocarbyl, C 1 .6 hydrocarbyloxy, C 16. hydrocarbylamino, C 1 .6
hydrocarbylsulfydryl, carbonyl hydrazide, C 1-6 hydrocarbyl carbonyl, C 1-6 hydrocarbylamino carbonyl, C 1 .6 hydrocarbylcarbonyl amino, C 1 6.
hydrocarbyloxy carbonyl, C 1 .6 hydrocarbylsulfinyl, C1-6 hydrocarbylamino
carbonylamino, C 3 .6 cycloalkyl, C 3 .6 cycloalkoxy, C 3 .6 cycloalkylamino, C 3 .6
cycloalkylsulfydryl, C 3 .6 cycloalkylcarbonyl, C 3 .6 cycloalkylamino carbonyl,
C 3 .6 cycloalkylcarbonyl amino, C 3 .6 cycloalkylamino carbonylamino, C 4 8.
heterocycloalkyl,C 4.8 heterocycloalkoxy,C 4.8 heterocycloalkylamino,C 48. heterocycloalkyl sulfydryl,C 4.8 heterocycloalkyl carbonyl,C 48. heterocycloalkylamino carbonyl, C 5 .10 aryl, C 5 .10 aryloxy, C 5.10 aryloxy hydrocarbyl,C 5 .10 arylamino,C 5 .10 aryl sulfydryl,C 5 .10 aryl carbonyl,C1 6. hydrocarbyl sulfonyl,C 1 .6 hydrocarbyl sulfonylamino,C 3.6 cycloalkyl sulfonyl,C 3 .6 cycloalkyl sulfonylamino,C 5.1 0 aryl sulfonyl,C 51. 0 aryl sulfonylamino, aminooxalyl amino, aminooxalyl,C 5 .10 arylamino carbonyl or C 5 . 1 0 arylamino carbonylamino; or, R 6is a fifth ring; or, R6 and R are connected and form a sixth ring together with a nitrogen atom both connected therewith, and the sixth ring is monocyclic, spiro, fused cyclic, bridged cyclic or polycyclic, and optionally contains 1, 2, 3 or more groups independently selected from heteroatom, C=O, S=O orSO 2, in addition to the nitrogen atom which R and R6 are both connected with; (6) m is 0, 1, 2,3, 4 or 5, and R 7 is selected from hydrogen, hydroxy, cyano, halogen, carboxyl, ester, sulfonyl amide,amide; or, R 7 is selected from the following unsubstituted or substituted groups: C1 6. hydrocarbyl,C1 .6 hydrocarbyloxy,C 1.6 hydrocarbylamino,C 1.6 hydrocarbylsulfydryl, carbonyl hydrazide,C 1 .6 hydrocarbyl carbonyl,C 1.6 hydrocarbylamino carbonyl,C 16. hydrocarbylcarbonyl amino,CI 6 hydrocarbyloxy carbonyl,C1 .6 hydrocarbylsulfinyl,C 1.6 hydrocarbylamino carbonylamino,C 3.6 cycloalkyl, C 3 .6 cycloalkoxy,C 3.6 cycloalkylamino,C 3.6 cycloalkylsulfydryl, C 3 .6 cycloalkylcarbonyl,C 3.6 cycloalkylamino carbonyl,C 3 .6 cycloalkylcarbonyl amino, C 3 .6 cycloalkylamino carbonylamino,C 48. heterocycloalkyl,C 48. heterocycloalkoxy,C 4.8 heterocycloalkylamino,C 4.8 heterocycloalkyl sulfydryl,C 4-8 heterocycloalkyl carbonyl,C 48. heterocycloalkylamino carbonyl,C 5.1 0 aryl, C 5.10 aryloxy, C 5.1 0 aryloxy hydrocarbyl, C 5 . 10 arylamino, C 5 .1 0 aryl sulfydryl,C 5 .1 0 aryl carbonyl,C 1 .6 hydrocarbyl sulfonyl,C 1 .6 hydrocarbylsulfonyl amide,C 3.6 cycloalkyl sulfonyl,C 3.6 cycloalkylsulfonyl amide, C 5 . 10 aryl sulfonyl,C 5. 10 arylsulfonyl amide, aminooxalyl amino,
aminooxalyl,C 5.1 0 arylamino carbonyl orC 5.1 0 arylamino carbonylamino; or, m is 2, 3, 4 or 5, and one or more pairs of neighboring R 7 are connected and form a seventhring together with carbon atoms connected therewith; or, R2and R7 are connected and form the second ring together with carbon atoms connected therewith; (7) X is selected from Y(CH 2 ).,- CH(OCH 3), -CH(SCH 3), N, 0or S, Y is a single bond, NH, 0 or S, and n is 0, 1, 2 or 3; (8) W is hydrogen or a group that is metabolized to a parent drug by chemical means and/or by the action of an enzyme in vivo; (9) Arl and Ar2 are independently selected from a phenyl ring, or a heteroaromatic ring containing 1, 2, 3 or more heteroatoms; (10) the first ring, the second ring, the third ring, the fourth ring, the fifth ring, and the seventh ring are independently an unsubstituted or substituted carbocyclic ring uninterrupted or interrupted by 1, 2, 3 or more selected from heteroatom, C=, S=O or SO 2 , and the first ring, the second ring, the third ring, the fourth ring, the fifth ring, and the seventh ring are independently monocyclic, spiro, fused cyclic, bridged cyclic or polycyclic.
According to the present disclosure, when there are a plurality of R7 (that is, m is greater than 1), whether R7 is the same or different is no particular required.
According to a specific aspect of the present disclosure, Arl and Ar2 are both a phenyl ring and the pyridone derivative is represented by Formula (II): W 0 0
(R7)m
According to another aspect of the present disclosure, at least one of Arl and Ar2 is a heteroaromatic ring.
According to the present disclosure, in the heterocyclic ring or the heteroaromatic ring, a heteroatom is dependently selected from N, 0, or S.
According to some embodiments of the present disclosure, A is CR1 , M is CR 2
, and R 1 and R2 are connected and form the first ring together with carbon atoms connected therewith.
According to some embodiments of the present disclosure, Q is CR3,RisCR 4R5
, and R 3 and R 4 are connected and form the second ring together with carbon atoms connected therewith.
According to certain embodiments of the present disclosure, R is CR 4R, and R 4 and R 6 are connected and form the sixth ring together with nitrogen and carbon atoms connected therewith.
According to further embodiments of the present disclosure, W in Formula (I) comprises, but not limited to, (a) -C(=O)-R 8; (b) -C(=O)-(CH 2)k-R, k is selected from 0-3; (c) -C(=O)-O-(CH 2)k-R, k is selected from 0-3; (d) -CH 2-0-R8 ; (e) -CH 2 -0-C(=0)-RS; (f) -CH 2 -0-C(=0)-O-RS; (g) -CH(-CH 3 )-O-C(=0)-RS; (h) -CH(-CH 3)-O-C(C=0)-O-(CH 2)k-R, k is selected from 0-3; (i) -CH 2-0-P(=O)(OH) 2; (j) -CH 2-0-P(=O)(OPh)(NHR 8 ); (k) -CH 2-0-P(=0)(OCH 20C(=0)0R 8)2 ; R 8is selected from the following unsubstituted or substituted groups: C 1 6. hydrocarbyl,C1 .6 hydrocarbyloxy, C 1 .6 hydrocarbylamino,C 1 .6 hydrocarbylsulfydryl, carbonyl hydrazide,C1 .6 hydrocarbyl carbonyl,CI 6 hydrocarbylamino carbonyl,CI 6
hydrocarbylcarbonyl amino,CI 6 hydrocarbyloxy carbonyl,Ci 6 hydrocarbylsulfinyl,C1. 6 hydrocarbylamino carbonylamino,C 3.6 cycloalkyl,
C 3 .6 cycloalkoxy,C 3.6 cycloalkylamino, C 3 .6 cycloalkylsulfydryl, C 3 .6 cycloalkylcarbonyl, C 3 .6 cycloalkylamino carbonyl, C 3 .6 cycloalkylcarbonyl
amino, C 3 .6 cycloalkylamino carbonylamino, C 4 8. heterocycloalkyl, C 4 8.
heterocycloalkoxy, C 4 .8 heterocycloalkylamino, C 4 .8 heterocycloalkyl
sulfydryl, C 4 .8 heterocycloalkyl carbonyl, C 4 8. heterocycloalkylamino
carbonyl, C 5 . 10 aryl, C 5 .10 aryloxy, C 5 .1 0 aryloxy hydrocarbyl, C 5 . 10 arylamino,
C 5 . 1 0 aryl sulfydryl, C 5 . 10 aryl carbonyl, C 1 .6 hydrocarbyl sulfonyl, C 1 .6 hydrocarbyl sulfonylamino, C 3 .6 cycloalkyl sulfonyl, C 3 .6 cycloalkyl sulfonylamino, C 5 . 10 aryl sulfonyl, C 5 . 10 aryl sulfonylamino, aminooxalyl
amino, aminooxalyl, C 5 . 10 arylamino carbonyl or C 5 . 1 0 arylamino
carbonylamino.
According to a preferable aspect of the present disclosure, when the sixth ring is a
spiro ring, a common carbon atom of the spiro ring and a nitrogen atom shared by
the spiro ring and a parent ring (the parent ring refers to a ring present in general formula (I), similarly hereinafter) are adjacent or spaced by one atom.
According to another specific embodiment of the present disclosure, when the
sixth ring is a spiro ring, a ring in the spiro ring that shares the nitrogen atom with
a parent ring has an oxygen atom or a nitrogen atom at a position opposite to the
shared nitrogen atom.
According to another preferable aspect of the present disclosure, when the sixth
ring is a spiro ring, a ring in the spiro ring that shares the nitrogen atom with a
parent ring is a 5-membered, 6-membered, 7-membered or 8-membered ring, and
another ring is a 3-membered, 4-membered, 5-membered or 6-membered
carboatomic, oxygen-containing heterocyclic or sulfur-containing heterocyclic
ring unsubstituted or substituted by a substituent selected from halogen, C 1 . 3
hydrocarbyl or C 1 .3 halohydrocarbyl.
Further preferably, when the another ring has a substituent, the substituent is
selected from methyl, fluoro, chloro, bromo, monofluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, methoxymethyl, methoxyethyl, chloromethyl.
According to some specific and preferable aspect of the present disclosure, in Formula (I), the sixth ring formed by connecting R6 and R together with the nitrogen atom connected therewith is selected from the following groups:
- -- 0 /N 0 -N--: 0 4N' 6 ;-N N 0 'N *yN 'N
According to a preferable embodiment of the present disclosure, the pyridone derivative is represented by Formula Ila or Formula Ilb: w K" 0 0 0 00
(R7)m (R7)m
Ila IIb
in Formula Ila and Formula Ilb, G is O or CH2; Z is selected from CH 2 , 0 or S; p and q are respectively 0, 1 or 2, and the two are not 0 at the same time, and when Z is 0 or S, p+q is greater than or equal to 2; definitions of W, R 7 and m are respectively the same as previous.
Further preferably, in Formula Ila and Formula Ilb, p+q = 1 or 2 or 3, and Z is CH2 ; or, p = 1 or 2, q = 1 or 2, and Z is 0 or S.
According to some more specific embodiments of the present disclosure, R 7 is selected from hydrogen, hydroxy, cyano, halogen,C1 .6 hydrocarbyl,C1 .6 halohydrocarbyl,C 3.6 cycloalkyl,C 1 .6 alkoxyC1 .6 hydrocarbyl, hydroxyC1 .6
hydrocarbyl,CI 6 hydrocarbyloxy.
Further preferably, in Formula Ila and Formula Ilb, R 7 is connected to a phenyl ring.
Preferably, m is 1 or 2 or 3. In a specific embodiment, m is 1 or 2, and R 7 is selected from fluoro, chloro, bromo, methyl or trifluoromethyl, etc..
Preferably, W is selected from the following groups: (a) -C(=O)-R 8; (b) -C(=O)-(CH 2)k-R, k is selected from 0-3; (c) -C(=O)-O-(CH 2)k-R, k is selected from 0-3; (e) -CH 2 -0-C(=O)-R8 ;(f) -CH 2-0-C(=0)-O-R; (g) -CH(-CH 3)-O-C(=O)-R 8 ; (h) -CH(-CH 3)-O-C(C=0)-O-(CH 2)k-R, k is selected from 0-3; (i) -CH 2-0-P(=O)(OH) 2; (j) -CH 2 -0-P(=O)(OPh)(NHR 8 ); (k) -CH 2 -0-P(=0)(OCH 2 0C(=0)0R 8) 2 ; R 8is selected from methyl, ethyl, isopropyl, or butyl.
In a specific embodiment, in Formula Ila and Formula Ilb, W is (f)
-CH 2-0-C(=0)-O-R, and Rs is methyl, ethyl, isopropyl or butyl.
The pyridone derivatives represented by the above Formula Ila or Formula IIb show the best activity, and the metabolic stability of the drug is remarkably
improved, and it is expected to have positive effects on the phase II metabolism
glucuronidation.
According to another aspect of the present disclosure, the pyridone derivative is
represented by following Formula Ic:
SPECIFICATION W 0 0
(R7 )m
in Formula Ic, a, b, c and d are respectively 0, 1, 2 or 3, and a and b are not 0 or 3 at the same time, and c and d are not 0 or 3 at the same time; E is CH2 or 0; K is CH2 or 0;
definitions of W, R 7 and m are respectively the same as previous.
Preferably, in Formula Ic, a+b = 1 or 2 or 3, and c+d = 1 or 2 or 3.
Preferably, in Formula Ic, R7 is selected from hydrogen, hydroxy, cyano, halogen,C 1.6 hydrocarbyl,C 1.6 halohydrocarbyl,C 1.6 alkoxyC1 6. hydrocarbyl, hydroxyC1. 6 hydrocarbyl,C 16 hydrocarbyloxy.
More specifically, in Formula Ic, R7 may be, for example, protium, deuterium, fluoro, chloro, bromo, methyl, ethyl, trifluoromethyl, methoxymethyl, etc..
Preferably, R 7 is connected to a phenyl ring.
Preferably, in Formula Ic, m is 0, 1, 2 or 3.
The compounds represented by Formula Ic, have a novel structure, and are highly active compounds aganist influenza type A and type B viruses.
According to an aspect of the present disclosure, when the fifth ring is a bridged ring, the bridged ring is bicyclic or tricyclic, and a bridgehead carbon atom or a non-bridgehead carbon atom of the bridged ring is connected to a corresponding nitrogen atom on a parent ring.
According to some specific implementations of the present disclosure, when the fifth ring is a bridged ring, the bridged ring is selected from bicyclo[1.1.1]pentane, bicyclo[2.1.0]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.0]hexane, bicyclo[3.1.1]heptane, bicyclo[3.2.0]heptane, bicyclo[2.2.1]heptane, bicyclo[3.2.1]octane, bicyclo[3.3.0] octane.
Further, when the fifth ring is a bridged ring, the bridged ring is unsubstituted or substituted by 1, 2, 3 or more substituents selected from fluoro, chloro, bromo, trifluoromethyl, -CH 2OH or -CH 20CH2 .
According to another aspect of the present disclosure, the pyridone derivative is represented by following Formula Ild or Formula Ile:
O 12 O 0
(IR 7 )rr G ___________
lid Ile
in Formula Ild and Formula Ile, R 12 is selected from hydrogen, hydroxy, cyano, halogen,C 1.6 hydrocarbyl,
C 1 -6halohydrocarbyl,C1.6 alkoxyC 1 .6 hydrocarbyl,CI 6 hydroxyl-substituted
hydrocarbyl,C 1 .6 hydrocarbyloxy; definitions of W, R7 and m are respectively the same as previous.
Preferably, R 12 is selected from hydrogen, fluoro, chloro, methyl, ethyl, isopropyl, trifluoromethyl, methoxymethyl or hydroxymethyl, etc..
Preferably, in Formula Ild or Ile, R7 is selected from hydrogen, hydroxy, cyano, halogen, C 1 .6 hydrocarbyl,C 16. halohydrocarbyl,C 1.6 alkoxyC1 6. hydrocarbyl, hydroxyC 1 .6 hydrocarbyl,C 1.6 hydrocarbyloxy. Preferably, R 7 is connected to a
phenyl ring.
Compounds represented by Formula Ild and Formula Ile are significantly optimized in space volume and spatial configuration of the groups compared to existing compounds, and thus have potent inhibition of influenza A activity, have a significant metabolic advantage ( Metabolic stability), and have good development prospects.
According to one aspect of the present disclosure, when the sixth ring formed by R 6 and R and the nitrogen atom connected therewith is a 4-membered, 5-membered, 6-membered or 7-membered monocyclic ring, Formula (I) further meets at least one of the following conditions: i) in addition to the nitrogen atom to which both R and Rare connected, the sixth ring optionally contains one or two of oxygen atom, another nitrogen atom, C=O, S=O andSO 2 ;
ii) the sixth ring has at least one substituent selected from hydroxy, cyano, carboxyl, ester, sulfonyl amide, amide,C 2 -6 alkenyl,C 36. cycloalkyl, C 3 6. halocycloalkyl, C 3 .6 cycloalkoxy, C1.6 hydrocarbyloxy C 16. hydrocarbyl, C 1.6 hydrocarbyloxy C1.6 hydrocarbyloxy, C 1 .6 hydrocarbylamino, C 1 .6
hydrocarbylsulfydryl, carbonyl hydrazide, C 1 .6 hydrocarbyl carbonyl, C 1 .6
hydrocarbylamino carbonyl, C1.6 hydrocarbylcarbonyl amino or C1.6
hydrocarbyloxy carbonyl;
iii) the sixth ring has an intra carbon-carbon ethylenic bond, or the sixth ring
has an exocyclic carbon-carbon ethylenic bond sharing one carbon atom with
the sixth ring;
iv) at least one of Arl and Ar2 is a nitrogen-containing heteroaromatic ring;
v) at least one of A and M is N.
Further, in the condition ii), the substituent in the sixth ring is selected from
OCH2 CH2 0CH 3, -CH 2 0CHF 2 , -CH 2 0CF 3 , -CH 2 OH, -OH, -COOH, -COOCH 3 ,
-CONH 2, -OCH 2F, -OCHF 2, -OCF 3, -CH 20CH3, tCH20-< -K 0
HA +00, etc..
According to a specific aspect of the present disclosure, when the sixth ring is a 4-membered, 5-membered, 6-membered or 7-membered monocyclic ring, the sixth ring contains a total of 2 heteroatoms and the 2 heteroatoms are in para or meta positions, and one of the heteroatoms is a nitrogen atom connected to both R and R 6, and the other heteroatom is oxygen or nitrogen. The representative sixth ring is, for example:
OH N O NOOCH3 OH N N OCH 3 N N OCH 3
10 -1 0 ~O~ 0; , a
O 0 N OCH 3 N OH 0 o\ o .
According to a more specific aspect of the present disclosure, the two heteroatoms contained in the sixth ring are all nitrogen atoms and the two nitrogen atoms are in opposite positions, while the sixth ring further has a C=O. The representative sixth ring is, for example:
N O N O0 4N O NH N,CH \ N _<
According to another specific aspect of the present disclosure, when the sixth ring is a 4-membered, 5-membered, 6-membered or 7-membered monocyclic ring, the sixth ring contains a total of1 heteroatoms which is the nitrogen atom connected to both R and R6 (that is, the nitrogen shared by the parent ring), while the sixth ring has an intra carbon-carbon ethylenic bond or an exocyclic carbon-carbon ethylenic bond. The representative sixth ring is, for example:
According to an aspect of the present disclosure, in Formula (I), the sixth ring is an unsubstituted morpholine ring, and further meets at least one of the following conditions: i) one of A and M is N, and the other is correspondingly CR1 or CR 2,while Q is CH; ii) at least one of Arl and Ar2 is a nitrogen-containing heteroaromatic ring containing 1 or 2 nitrogen atoms.
According to another aspect of the present disclosure, when the sixth ring is a fused ring, the fused ring is a bicyclic ring, and one ring sharing a nitrogen atom with the parent ring is a saturated 5-membered or 6-membered ring and optionally contains one or two groups selected from 0, another N, C=O, S=0, orSO 2 , and the other ring is a 3-membered, 4-membered, 5-membered or 6-membered saturated or unsaturated ring and optionally contains one or two groups selected from 0, N, C=O, S=O or SO 2 .
According to another aspect of the present disclosure, when the sixth ring is a fused ring, one ring of the fused ring sharing the N atom with the parent ring is a piperidine or piperazine ring, and the other ring is a 5-membered or 6-membered heteroaromatic ring or a saturated heterocyclic ring. Further, the 5-membered or 6-membered heteroaromatic ring or the saturated heterocyclic ring is unsubstituted or substituted by 1, 2, 3 or more substituents selected from hydroxy, cyano, carboxyl, ester, sulfonyl amide, amide,C 1 -6alkyl,C2-6alkenyl,C1 -6 halohydrocarbyl,C 1 .3 alkoxy,C 3.6 cyclohydrocarbyloxy,CI 6 hydrocarbyloxyC1 .6 hydrocarbyl,C 1 .6 hydrocarbylamino,CI 6 hydrocarbylsulfydryl, carbonyl hydrazide,C 1 .6 hydrocarbyl carbonyl,C 1 .6 hydrocarbyl sulfonyl amide,C1 .6 hydrocarbylamino carbonyl,CI 6 hydrocarbylcarbonyl amino orC1.6
hydrocarbyloxy carbonyl.
According to some specific embodiments of the present disclosure, the sixth ring is selected from the following groups:
N O N O' O OD 0 O OH
-r
According to some embodiments of the present disclosure, the sixth ring is a piperidine ring or amorpholine ring, asubstituent in the ring is preferably selected from, but not limited to, the following groups: alkoxyalkyl, haloalkoxyalkyl, hydroxyalkyl, ester, carboxyl, amide, cyano, cycloalkyl, cycloalkoxy, halocycloalkyl, hydroxy, hydroxy and alkyl/haloalkyl are connected to the same carbon atom, or cycloalkyl and hydroxyl are connected to the same carbon atom. The piperidine ring or the morpholine ring is preferably selected from the following groups: OCH 3 NOCH3 NN N N OH NNOH3
NO 0/N oO ;
OC3QH HOH OH;
According to some embodiments of the present disclosure, the sixth ring is a piperidine heterocyclicring (including an aromaticheterocyclic ring orasaturated heterocyclic ring) or apiperazineheterocyclic ring (including anaromatic 17
heterocyclic ring or a saturated heterocyclic ring), and the substituent on the ring is preferably selected from, but not limited to, the following groups: alkyl, alkoxy, haloalkyl, hydroxyl or methanesulfonylamide. The piperidine heterocyclic ring (including an aromatic heterocyclic ring or a saturated heterocyclic ring) or the piperazine heterocyclic ring is preferably selected from the following groups:
0N OH N~ O NN OO
0*
H H 4 NHSO CH N N, ,N
/ OCH 3 2 3 NN N
CF3
0
NN N N N CH 3
0
According to some embodiments of the present disclosure, the sixth ring is a piperazine ring, and the ring contains an oxo group (carbonyl), and such piperazine ring is preferably selected from, but not limited to:
N O N O N O NH N'CH3 \ N
According to some embodiments of the present disclosure, the sixth ring is an unsaturated piperidine ring, and the unsaturated bond is cyclic or exocyclic, and such unsaturated piperidine ring is preferably selected from, but not limited to:
According to some preferable embodiments of the present disclosure, R6 is
selected from:
O- ;0
; 0 00
FLi F F O
10p 00 fo fu c NH 0OH0
0-
F 0NJt F 0 C a OH;
00 NA-O NHF0 H
O I olC N O-/) NJO-C OS) N O\ N
According tosomeembodimentsof the present disclosure, the tesixth ring isa morpholine ring,andthcompoundsofFormula(1)specificallyrefertothe following four compounds: OH 0OH 0OH 0OH 0 OOOHOAN- OHOAN- y -A OT--) N:,N 0o N.. N_, 0 ND
According to the present disclosure, the pyridone derivative is preferably selected
from the following compounds: OHO OO OHO0 OHO0
NN) N N- NZ N, W-0 N NN N
1-1 1-2 1-3 1-4
O0H0OH 0 OH 0
00NJ~ N N
F SF -CS F(CS F : SO FF F F 1-5 1-6 1-7 1-8
0
OHO0H OHO0 9 OH OH0 N ~ON 0./& OH"J
0 N
.SS F sF s1-12 1-9 1-10 F F
OH 0 '0 OH 0 OHO0 OHO0
FF sF s F s
51-13 F 1-4F 1-5F 1-16
OHO0 OHO0 S- ~ OHO F OHO0
yl-AN"-'0Q 0 N '.0' N'~ N N F
1-17 1-18 1-19 1-20
OHO0 OHO0 OHO0 OHO0 r N Nj$/ NN"0NN'.2:K 0 N NN'NNN NN NN F N F F N
1-21 1-22 1-23 1-24
OHO0 OHO0 OHO0 OHO0
N' N'-<> N N'.X
F 1-25 1-26 1-27 1-28
OH 0 0OH0 -4 OHO0~ -Z OH 0 OH
N o N'Q11/ '(>N 'KJN N
1-29 1-30 1-31 1-32
OH 0 0OH0 OH0 OHO0 OH jNK N+J -- N N-KJNN0
F SF F sF 1-33 1-34 1-35 1-36
OH 0H OHO 00OH0 1 N 0 J7 OH 0 --- N- N-a N NkJ 0 N-a N
TZ ~ ~ ~ ~~ N NN)1 N) L,
1-37 1-38 1-39 1-40
OHO0 OHO0 OHO0 OHO0
NCN o0 \ o
N N N ~ N
S S s s 1-41 1-42 1-43 1-44
OHO0 OHO0 OHO0 OHO0 N~s< 0 N 1.1 0-: N-\S- O N-_ < O TN N\SCF 3 NN ~zzN N)N ) N N)
F sF sF sF
1-45 1-46 1-47 1-48
OHO0 OH 0,A OH0 Hj~ OH0 N NN 0 -N S N NldTA N N / N N )N N 0N0 F
S S S S 1-49 1-50 1-51 1-52
OHO0 OHO0 _ OHO0 He OH 0 H O 0 1 1. N -N- fN NNl--S N 0N' NZZT N 0'- ,I' NN 0~ NNN )N N. N N
F - \/ F \ F - FF -l
F F F S 1-53 1-54 1-55 1-56
SPECIFICATION OHO0 OH 0 0OHO0 OHO0 ~N~ NA N H s -'P, N HN N 'N '~~~N.N)'N N~
1-57 1-58 1-59 1-60
OHO OHO0 OHO0 OHO0
N0N-'~ N N IN'
FF .- F -o
F S F F F+O 1-61 1-62 1-63 F 1-64
OH 0 OH 0 OH 0 OHF
'H~~O 0H'H
N N N N1 N 7 F F- SsSo FF F F~s 1-65 F 1-66 1-67 F 1-68
OH 0 0 F OHO ~CF, OH N IO OH 0
1-69 1-70 1-71 1-72
F 4 CF 3 OH 0 J ~OCH3 OH 0 OH 0 OH 0
N N N yTN N N NH)N N 'N N
51-73 1-74 1-75 1-76
N NH CF,3 H0 O OH0OH 0~ 1
Oy N
FjS F SF:CS Fs F 1-77 F 1-78 F 1-79 18
OH OJ OH 0 NO OH 0
0 So F F 1-81 F 1-82 1-83 1-84
OH0 CF 3 0OHO0 Q ,O O0OH0 F
N N0NNN FNN~
F N N F N ~ F N
1-85 1-86 1-87 1-88
OH 0 j~F 0OH 0 A CF 3 OHO0O OH 0 JNI
Nl NN NNNN
1-89 1-90 1-91 1-92
F ~ CF,
OH 0 [ 7 "C 3 OH 0 OH 0 N r OC 0 O- NO TN 0
I-? S F s F 1-93 F 1-94 F 195 19
OHO0 OHO0 OHO0 OHO0 OCH,
N' N0 N N N Ny" AL N N N, ~ NN~A~ N, NA~ N, N 0A
11I-1 11-2 11-3 11-4
OHO0 OHO0 OH0 OH0 OCH 3 0 0 0 ON- N Nz-')ANf-- 'NN Oz N ZN>0 NN N ' A.oN NAO Nk' N~NAo N 0
F X F - /F -F'- \ F sF F F 11-5 11-6 11-7 11-8
OHO0 OHO0 OCH, OHO0 OHO0
N N, N-P N N JL N N Ny'zz
zz, N~A, NN, N""NAo NN.< N' N'NL'O
F sF sF sF 11-9 11-10 11-11 11-12
OHO0 OHO OCH, OHO0 OHO0
N N N , k-,N, N -- NN N'NAo N~ N NNNAlO N4" N"N.O
F F FFx
11-13 11-14 11-15 11-16
OHO0 OHO0 OCH, OHO0 OHO0 N0 N N N N 0NI~ N N
F,~ N L,1 F F N F N
0,\ '-. 0-
1117 11-18 11-19 11-20
OHO0 OHO0 OHO0 OCH 3 OH 0~-
N> N cl N NN. Nc1l]O N
x x /' - x
11-21 11-22 11-23 11-24
0~~~~ N0
N .NO N N'NAo N 'l NN'l
F sF sF sF 511-25 11-26 11-27 11-28
OHO0 OHO0 OHO0 0 OHO0 0
OH 0 N OH N 0 Oy - N- r OCH 3 0 N N NkT
NNLNJo N N N),,, N N'N)l N NNeo
q'F ' F- '/7C F -7
F sF sF sF 11-29 11-30 11-31 11-32
OHO0 OHO0 0 OHO0 0\ 00 ' N NOH N -- T--V
0'"" 0 ON N LN)o *'7
FF x
13311-34 11-35 11-36
SPECIFICATION 0 OOHO0 OHON OHO0 N0
N1 N"AKO H OH 0 Oy- N---O- N.NV N'-oN " L N NNA.'O
11-37 11-38 11-39 11-40
OHO0 OHO0 OHO0 OHO0
N N 0 N N NN NNN
11-41 11-42 11-43 11-44
OHO0 OHO0O 0O O 'ZZ 0 N- Nkz N)N 0 0 N N 0 N N N NNN'.NNN-., LN N
F 7 -F )XD/O F F sF sF sF 11-45 11-46 11-47 11-48
OHO0 OHO0 OHO0 OHO0 0 01N ,N N N OH 01N N CH 3 1N N NHSOCH, N 'NN N ' )N N N N N
F sF sF sF
11-49 11-50 11-51 11-52
OHO0 OHO0 OHO0 0 H N OHO 7 N ~~~N NN N N N 6 N N~A.N N N.N4N""L' NN CF3
~\ - s / s\
OHO0 OHO0 0~~~. OHO N H NN OHO A 7 N.
-~ y F-/
11-57 11-58 11-59 11-60
OHO0 OHO0 OHO0 OHO0 N- 0. r- 0
F- F sF sF
11-61 11-62 11-63 11-64
SPECIFICATION OHO0 OHO0 OHO0 OHO0
..-... 0 N
F F - - F... F' F sF sF S F 11-65 11-66 11-67 11-68
OH 0 OHO0 OHO0 OHO0
O z ,N, -,h N, N N NNN. NNt' N.NA.O N '-o
s F\- s F - F 0o
11-69 11-70 11-71 11-72
OHO0 OHO0 OHO0 OHO0
O N- N-'N '-TN~ N N NA~ NN.)< N N ON %N. N'k'o ) N N) N'0N
N F S 1 N' Fj: sNN F F CF 3 11-73 11-74 11-75 11-76
OHO0 OHO0 OHO0 OHO0
N NYN, N1 > N N> OY N N N.N..-<O N N.N 'O N N LNA.0 N, k
F 11-77 11-78 11-79 11-80
OHO0 OHO0 OHO0 OHO0 N.X NN NfYK O 0 "N NN
511-81 11-82 11-83 11-84
OCH 3 OHO0 OHO0 OHO0 OHO NN 0CH F 0tN Nt N OCH 3 N N FN N NN NN FF F- 7 s \/ F
F F FF 11-85 11-86 11-87 11-88
OHO0 OHO0 OHO0O O~~o oo%.ly..--..N y--- NII. N- N 0 N- N 0 1 ,N WzN 0 N 0HO> HC0
N' sF sF IF sF F s F F FFF 11-90 11-91 11-92 11-89
SPECIFICATION OHO0 OHO0 OHO0 OHO0
0 0 Nl N BrNz,, N0 N N NF N
0 Fi N-C N.A.S. Br -[N: N. H3 .N F NN.:
F F F F 11-93 11-94 11-95 11-96
OHO0 OHO0 OHO0 OHO0
N0 N
NH N4NN
F): S H2N F-1: F -~ F FF F OCH, F SCH,
11-97 11-98 11-99 11-100
OHO0 OHO0 OHO0O N-- N 0 N NNr 0 H N. :ND '1N," N, , NN N ,NCH, QN NH N NN Iz- 0-pV F~ q F F F s.
11-101 11-102 11-103 11-104
OH 0OH 0OHO0 OHO0 OH 0 0 NH N0 0 y- N OCNH r-N, L ktN N. N1 N OCH 3 NN N N 'N
11105 11-106 11-107 11-108
OHO0 OHO0 OHO0 OHO0
O 010 N N NN,..N iLiILOCH 20OCH OH N F N OH
F - F. - /F - OC 3 F
F sF sF sF 511109 11-110 11-111 11-112
0 0, 3 0 HC0 HC 10A01-\ 0 10A0-o 10 0-\ 0 0 0 1\ OCH 3
00 00 0--AN-0 00 'AN N NNk 0 N 1 0NN NN~Z1 NN.NJ N )-oN4N)-0 NN.N.Lo N.N)o
- F -F -q/ F
F sF sF F 111-1 111-2 111-3 111-4
H 0 N \ 0, 00 , , 0\ OCH, A -\0 0 00 \0 00OO-oo 0 OO\
0 N- 0 N~f N N 0 N
1N NNA0 N N..N) 0 N N.N0' NN.Y
sF sF sF F 111-5 111-6 111-7 111-8
0, , 0 H 0 HC 0
0N$ N Ny"J fN 01: IN 0 N
1N NNA,0NNN.k.0NN.r0 N, N,.A~
111-9 111-10 111-11 111-12
HC~ HC 0 H 0 HC 0
- 0 -\ AO\o 10' 0 0o-o -\ 00OH,
00 00 000 N~~ 1 0 N N~Nf-,0 N ,~ .li 0 N N.N .0 Lz N N.)%r, NN..)% NO N L
111-13 111-14 111-15 111-16
0 HC 0 03 3 0 H 3 C *A 4 \ 0 3 , 4 0HA-o o1 o\ AC,\% C 0-N N\0 0\ OCH 00t 00000 N ,ll 0 N-/N N 0 NN N ,. N 0 N,,.)~ N N.).~ .
111-17 111-18 111-19 111-20
H3C H3 C H 3C~ H3 C 0OH Ao\0 0A \0 0 0A-\ 0 0A'\o 0oCH
N~0N ~NN 0 N N NN~ N - N _ N N. £ iN N c N0 Ni /l N lN \/ c
5111-21 111-22 111-23 111-24
HC0 H3 C 0 H3 C 0 H 3C o-\ 0-\o0 0-1 0 0 0 o 0,0 'NNN~
F sF S F F 111-25 111-26 111-27 111-28
HC oo- 0A 0 HC3 -0 0 3 .J 0 0-~ 0 0 0-\o 0 H
o *' o- 0 N N NA H 0 N N N NN N N N~~0 NN"N..o NN2"AO N" NNNY
F sF sF sF 111-29 111-30 111-31 111-32
0o- o O 0 O 0 0 0 H 3 C*0 0 0 0 o o N- OCH, N N-- OH 0 N OCHF 2 0 - N -- N O
N 'N.l N'NAO N ' " N '
F F F F 111-33 111-34 111-35 111-36
H3 C H3 C HC H3 C A1 0 o0 0o-O 0 A010 0
O`1 NNA F olNN,, O O'N NN-"-)\ ~ O
111-37 111-38 111-39 111-40
O ~,0H3 0 H 3 c* 0 0 oo o OCH 3 o'o, " 0 - ooo NN N OCIH 3 "" N N
N, 01 N N.'N NF
F F\I~ F sF sF sF
5111-41 111-42 111-43 111-44
H3C 0 0 H3 C H3 O~ o o 3C 10Ao-\o0 'o-ooHoCA o
0 Oy'-)AN 0 0 N-- oY- 0~N N ~~" 1 0~' N-N N 0 N 0N-N HO >1H 3 00X
IF s F s F IF s
111-45 111-46 111-47 111-48
SPECIFICATION 0 0 0 0 O O C2H5O O O (H 3 C) 2 HCO O O OAO o
N . ON'Nlo Nk N NO
F x F F
111-49 111-50 111-51 111-52
0
O O2O 0 2OO 0 (H 3 C) 2 HCO kO- OAO
N. N . ,N N N 0' N. O NO O
F-F F~ F F F F 111-54 F 111-55 111-56 111-53
H 3C O H 3CO O F H 3CO H3 C0O 'o~~o-o m C 0% FOO-o1
' F -S F1 s F F F~ ): F )[ 111-57 111-58 F 111-59 F 111-60
H3C 0 H3 N H3C 0 0 F 0-\ F F F 0 O (H0C)2HCO O F 0O- 1.
F F3 S 111-62 111-71 111-62 111-61
30 0 Ao-\ 0 0 2H A o-\o (H 3 C) 2 hc0-\o 0 A-\ 00 N'- 00- 0 J-0No N. N ) -lA
N. N N N LN N .1 N N .
F "' 7 "F F F F FS F(F
5111-65 111-66 F 111-67 F 111-68
HC 0 H 3 C, 4 0I H3C*0
0oo 0'O\o 0 F H3CA HC 0 lO 0000
000NJN0:40 0 'N 'N N 0 'NN 2J0 'N 'N 'N 'lN
111-69 111-70 111-71 111-72
SPECIFICATION 0 0 HCOA( 0 0OF 0 0 0 0-p\ HO~ ~ j\j00o 00P 0 N N H0 0 %,. 0 F 3 0 -OP oH30o 0-- 006A/ 0-- N 0 Oyl TN N0 N )N ) 0"' NN ) LNN
) 7 7 ,N N
F Cs F-( S F -:s F CS F F F F Iv-1 IV-2 IV-3 IV-4
0
0 0 H0 00H 0 'o H 3COA 0 0/ o NOA0 'A If 0 0 Oj 017 0'
NN0 N -- TN OY-IN 7N' N 'N
IV-5 IV6 IV-7 IV-8
0 0 00 0 0 H " 0 l I 0-'0HCO 0-pl,~~~0N 0 0 1 03OA0, Ha 0 -p\ Hd0'~ N 0 N N-4,1 H 3 0 ~oc N 0 0 N N 0 0NN
F'- \/ F ~ /IF F S F s F4F 1 F IV-9 IV-10 Iv-11 IV-12
0 0 0 0/ 0 H04 HCO"'(, 0 H 3C01 0f Hd \0-\o HO HCy ,I\-o oI"0\HC 1Io0\
N, N>l N, N"' 0 NK 0w 0 ~ Nw 0 0, N N No
IV-13 IV-14 IV-15 IV-16
HopHO-P\ HO-P HO -- 0 HdO -- \ 0 HO\ON--O HO - 0 OO~
N N ~ 00 01 NN" N N N NN.~ NN'~ ~ N F N
IV-17 IV-18 V1IV2
SPECIFICATION 0 H O HO-' 0 'it/ H0O- O HO 0-- H 000 0 HO- O O HO O H6 0OH OCHa O O. N N OCH3 0 U ONN O . N O N .N%~~ONN,O N. NNAo N, N NY
F SF SF S F IV-21 IV-22 IV-23 IV-24
0 0 0 ~ 0~
H 1HO' 0 H 3CO O H O-Oo H3 C,0 HC 0 HO 0 HCO NO. 6\0-\ 0 0 0
F -F- / F- F F F F F IV-25 IV-26 F IV-27 IV-28
0 0 HOP. HO-. O HO' 0 HO-p" HO-P O 0 H 0 O OCH H0'O O O HO 0 0 0 O NN OCHa ONN NH N O
F - F F 47 -\ F- 1\ F F F S F IV-29 IV-30 IV-31 IV-32
HO-I HO-P HO-I HO-P 0 HO O-0 o HO -O 0 H6O O- HO O Oy N. _ 0~N N'_] N. ' N
) N.N k- N. Nk." HC):N N~~O F N NNA.-O Ci) ''"
F - _- F F' X FS F F F F IV-33 IV-34 IV-35 IV-36
The present disclosure further provides a pharmaceutical composition comprising the pyridone derivative represented by Formula (I) or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof.
Further, the pharmaceutical composition is an antiviral pharmaceutical composition further optionally comprising one or more therapeutic agents selected from the group consisting of a neuraminidase inhibitor, a nucleoside drug, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs.
Preferably, the antiviral pharmaceutical composition comprises at least one therapeutic agent.
The present disclosure further relates to use of the pyridone derivative represented by Formula (I) or the stereoisomer, the pharmaceutically acceptable salt, the solvate, the crystal or a combination thereof in the preparation of a drug for preventing and/or treating a viral infection disease, the viral infection disease is preferably infectious diseases caused by influenza type A viruses and/or influenza type B viruses.
The present disclosure further relates to use of the pyridone derivative represented by Formula (I) or the stereoisomer, the pharmaceutically acceptable salt, the solvate, the crystal or a combination thereof in the preparation of an antiviral drug, the antiviral drug is preferably a drug or an agent inhibiting influenza cap-dependent endonuclease activities.
In the present disclosure, for convenience of description, in some places, the pyridone derivative represented by Formula (I) or the stereoisomer, the pharmaceutically acceptable salt, the solvate, the crystal or any combination thereof is collectively referred to as the compound of the present disclosure.
In the pharmaceutical composition according to the present disclosure, the compound of the present disclosure is preferably present in a therapeutically effective amount.
The above pharmaceutical composition usually comprises a pharmaceutically acceptable carrier such as a pharmaceutically acceptable diluent, an excipient, a filler, a binder, a disintegrant, an absorption enhancer, a surfactant, a lubricant, a fragrance, a sweetener, etc..
Further, the pharmaceutical composition may employ any kind of dosage form, which may specifically be a tablet, a powder, a capsule, a granule, an oral liquid, an injection, a powder, a suppository, a pill, a cream, a paste, a gel, a pulvis, an
inhalant, a suspension, a dry suspension, a patch, a lotion, a nano preparation, etc.. The dosage form of the pharmaceutical composition is preferably a tablet, a capsule or an injection.
The above mentioned dosage forms of the drug can be prepared by conventional methods in the pharmaceutical field.
In a specific embodiment, the pharmaceutical composition according to the present disclosure may be constituted by, for example, the following ratio (mass ratio): compound of the present disclosure 5-95% lactose 1-60% starch 0-20% microcrystalline cellulose 1-40% carboxymethyl starch sodium 1-5% polyethylene glycol (PEG6000) 0-10% magnesium stearate 1-5%
The present disclosure further provides a process for the pyridone derivative, i.e., a compound of Formula (I) according to the present disclosure, which employs the following route: Z'O O OHO 00O
R6 O NRe OH O N'R6O 0z 0 AY- 1 N,. M,,Q, AM,,Q, A T 3 PorH 2 SO4 AM' A R O , R. +
AIM,QN RX A1 (R7 )m. Ar!Ar (RA)m
A B C D (1)
According to a specific embodiment of the present disclosure, the above reaction can be implemented according to the following steps: Step-1: A and B are dissolved in ethyl acetate solution of 50% T 3P and react at 60-100 °C for 1-10 hours to give Intermediate C. Step-2: intermediate C and lithium chloride are reacted in DMA solution at 100 °C
for 12 hours, and the mixture is purified to give Compound D. Step-3: the obtained Compound D and acyl chloride or halide are reacted in the presence of an alkali to give a hydroxy-protected Prodrug (I), wherein the alkali comprises an organic alkali and an inorganic alkali, and the organic alkali is selected from triethylamine, DIPEA, DBU, and pyridine, etc.; and the inorganic alkali is selected from sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, potassium hydride, sodium bicarbonate, etc..
Due to the implementations of the above technical solutions, the present disclosure has the following advantages over the prior art: the present disclosure provides a novel pyridone derivative, which has strong inhibitory activity against influenza virus A and influenza virus B, and can be used alone for clinical treatment or in combination with other anti-influenza drugs such as neuraminidase inhibitors, nucleoside drugs and PB2 inhibitors, and may rapidly cure influenza patients in the clinic. These compounds are superior to the exsiting pyridone derivatives in at least one aspect of activity, pharmacokinetic properties (such as bioavailability) and cytotoxicity.
Definition of Terms Unless otherwise defined, all technical and scientific terms used herein have
the same meaning as commonly understood by one of ordinary skill in the art
to which this disclosure belongs.
The term "unsubstituted", when used to define a group, means that the defined
group is not replaced by a group other than a hydrogen atom, in which case the
group has the same meaning generally understood by one of ordinary skill in
the art to which the present disclosure belongs. For example, an unsubstituted
C 1 .6 alkyl is a group generally understood by those skilled in the art such as methyl, ethyl or the like.
The term "substituted", when used to define a group, means that 1, 2, 3 or more hydrogen atoms on the defined group are replaced by a substituent, and the meaning of this group should be understood in conjunction with the substituent. In the present disclosure, unless otherwise specified, when referring to "substituted", it is meant that hydrogen atoms in a group defined thereby are replaced by 1, 2, 3 or more substituents selected from the group consisting of: cyano, halogen, hydroxy, carboxyl, ester, sulfonyl, sulphonyl amide, amide, carbonyl (-C(=0)-),C 1.6 hydrocarbyl S(=O)(=NH)-, amino, carbonyl hydrazide,C 1.6 hydrocarbyl, halogenatedC1. 6 hydrocarbyl, hydroxyl-substitutedC1. 6 hydrocarbyl, acylamino-substituted C1-6hydrocarbyl, C 1 .6 hydrocarbyloxy, halogenatedC1-6hydrocarbyloxy,C 1.6 hydrocarbyloxy C 1 .6 hydrocarbyl,C 1.6 hydrocarbyloxyC 1 .6 hydrocarbyloxy,C 16. hydrocarbylamino,CI 6 hydrocarbylsulfydryl,C 1 .6 hydrocarbyl carbonyl,C1. 6 hydrocarbylamino carbonyl,CI 6 hydrocarbyl amide, halogenatedC 1 6. hydrocarbyl amide,C1 .6 hydrocarbyloxy acyl,C 1.6 hydrocarbylamino acylamino,C 1.6 hydrocarbyl sulfonyl,C 1.6 hydrocarbyl sulphonyl amide,C 3.6 cycloalkyl, halogenatedC 3 .6 cycloalkyl,C 3 .6 cycloalkoxy, halogenatedC 36. cycloalkoxy,C 3-6 cycloalkylC 1-6hydrocarbyl,C 3 .6 cycloalkoxyC1 .6 hydrocarbyl,C 3 .6 cycloalkylC 1 .6 hydrocarbyloxy,C 3 .6 cycloalkylC 16. hydrocarbyloxyC 1 -6hydrocarbyloxy,C3.6 cycloalkylamino,C 3.6 cycloalkyl C 1 .6 hydrocarbylamino,C3-6 cycloalkylsulfydryl, halogenatedC3-6 cycloalkylsulfydryl,C3-6 cycloalkylC 1-6hydrocarbylsulfydryl,C 3 .6 cycloalkyl sulfonyl, C 3 -6 cycloalkylC 1 -6hydrocarbylsulfonyl, C 3 .6 cycloalkyl sulphonyl amide, C 3 .6 cycloalkyl C 1 .6 hydrocarbyl sulphonyl amide, C 3 .6 cycloalkylcarbonyl, C 3-6 cycloalkyl C 1-6 hydrocarbylcarbonyl, C 3 .6 cycloalkylamino carbonyl, C 3 .6 cycloalkyl C 1-6 hydrocarbylamino carbonyl,
C 3 .6 cycloalkyl amide,C 3 .6 cycloalkyl C 1 .6 hydrocarbyl amide, C 3 .6 cycloalkylamino amide, C 4 .8 heterocycloalkyl, C 4 .8 heterocycloalkoxy,
halogenatedC 4 .8 heterocycloalkoxy,C 4 .8 heterocycloalkoxyC 1 .6 hydrocarbyl, halogenatedC 4 .8 heterocycloalkoxyC1. 6 hydrocarbyl,C 48. heterocycloalkyl C 1 .6 hydrocarbyloxy, halogenatedC 48. heterocycloalkylC -16hydrocarbyloxy, C 4 .8 heterocycloalkylC 1.6 hydrocarbyl,C 4 .8 heterocycloalkylC 1 .6 hydrocarbyloxyC 1 .6 hydrocarbyl,C 4 .8 heterocycloalkylamino,C 48. heterocycloalkyl sulfydryl,C 4 .8 heterocycloalkylC 1.6 hydrocarbyl sulfydryl, C 4 .8 heterocycloalkyl sulfonyl,C 4 .8 heterocycloalkylC 1.6 hydrocarbylsulfonyl, C 4 .8 heterocycloalkyl sulfonyl amide,C 4 .8 heterocycloalkylC 1.6 hydrocarbyl sulfonyl amide,C 4 .8 heterocycloalkyl carbonyl,C 48. heterocycloalkylC 1.6 hydrocarbyl carbonyl, carbonyl-substitutedC 4 .8 heterocycloalkyl,C 48. heterocycloalkylamino carbonyl,C 4 .8 heterocycloalkyl amide,C 4 .8 heterocycloalkylC 1 .6 hydrocarbyl amide,C 5. 10 aryl,C 5 .10 aryloxy,C 5 .10 aryloxyC 1 .6 hydrocarbyl,C 5 .1 0 arylC 1.6 hydrocarbyl,C 5.1 0 aryl C 1 .6 hydrocarbyloxy,C 5 .1 0 arylamino,C 5 .1 0 aryl sulfydryl,C 5 .1 0 arylC1 .6 hydrocarbyl sulfydryl,C 5 .10 aryl sulfonyl,C 5. 10 arylC 1 .6 hydrocarbyl sulfonyl, C 5 .1 0 aryl sulfonyl amide,C 5.1 0 arylC1 .6 hydrocarbyl sulfonyl amide,C 5 .10 aryl carbonyl,C 5 .1 0 arylC 1.6 hydrocarbyl carbonyl,C 510 arylamino carbonyl,C 5 .10 aryl amide or C 5.1 0 arylamino amide.
Preferably, the above substituent is selected from cyano, halogen (preferably F, Cl, Br), hydroxy, carboxyl, ester, sulfonyl, sulphonylamino, carbonylamino, carbonyl,C 1.6 hydrocarbyl sulfinylamino, amino, carbonyl hydrazide,C 1.6 hydrocarbyl, halogenatedC 1 -6hydrocarbyl, hydroxyl-substituted C1-6 hydrocarbyl, amide-substitutedC1 -6hydrocarbyl,C1 -6hydrocarbyloxy, halogenatedC 1 .6 hydrocarbyloxy,C 1.6 hydrocarbyloxyC 1 .6 hydrocarbyl orC1.6 hydrocarbyloxyC 1 -6hydrocarbyloxy.
Further preferably, the above substituent is selected from cyano, F, Cl, Br, hydroxy, carboxyl, ester, sulfonyl, sulphonylamino, amide, carbonyl, methylsulfinylamino, ethylsulfinylamino, isopropylsulfinylamino,
tert-butylsulfinylamino, amino, acylhydrazino, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, cyclobutyl, n-pentyl, isopentyl, neopentyl, cyclohexyl, halomethyl (specifically, for example, trifluoromethyl), haloethyl, halo-n-propyl, halo-isopropyl, halocyclopropyl, halo-n-butyl, halo-isobutyl, halo-tert-butyl, halocyclobutyl, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl, hydroxycyclopropyl, hydroxy-n-butyl, hydroxyisobutyl, hydroxy-tert-butyl, hydroxycyclobutyl, hydroxy-n-pentyl, hydroxyisopentyl, hydroxy neopentyl, hydroxycyclohexyl, methoxy, ethoxy, propoxy.
The substituent is usually placed before the group be substituted when come to specific naming, for example, "C1 .3 alkoxyC 3 .8 cycloalkyl C 1 .6 alkyl" means C 1 .6 alkyl is substituted byC 3 .8 cycloalkyl, andC 3 .8 cycloalkyl is further substituted byC 1 .3 alkoxy, for example: the structural formula of methoxycyclobutylmethyl is: H3CO CH2-*
The term "uninterrupted", when used to define a group, means that a covalent bond of the defined group is not interrupted by another group, in which case the group has the same meaning generally understood by one of ordinary skill in the art to which the present disclosure belongs. For example, an unsubstituted cycloalkyl is a group generally understood by those skilled in the art such as cyclobutyl, cyclopentyl or the like.
The term "interrupt" or "interrupted", when used to define a group, means that one or more covalent bonds of the defined group are interrupted by interrupting atoms or groups, and the meaning of this group should be understood in conjunction with the interrupting atoms or groups. In the present disclosure, unless otherwise specified, when referring to "interrupted", it is meant that the covalent bonds in the group defined thereby are replaced by 1,
2, 3 or more selected from heteroatoms (0, N, S), C=O, S=O orSO 2 . The position of the interruption may be any chemically achievable position, and when there are multiple interrupting atoms or groups, the relative positions between the multiple interrupting atoms or groups are not limited as long as they are chemically achievable.
The term "stereoisomer" refers to an isomer produced by the different arrangement of atoms in a molecule in space, and includes cis-trans isomers, enantiomers and conformers. All stereoisomers are within the scope of the present disclosure. The compounds of the present disclosure may be a single stereoisomer or a mixture of other isomers such as a racemate, or a mixture of all other stereoisomers.
The term "salt" refers to a pharmaceutically acceptable salt formed by a compound of the present disclosure with an acid, which may be an organic or inorganic acid, specifically selected from, for example, phosphoric acid, sulfuric acid, hydrochloric acid, hydrobromic acid, citric acid, maleic acid, malonic acid, mandelic acid, succinic acid, fumaric acid, acetic acid, lactic acid, nitric acid, sulfonic acid, p-toluenesulfonic acid, malic acid, methanesulfonic acid or analogues thereof.
The term "solvate" refers to a form of a compound of the present disclosure that forms a solid or liquid complex by coordination with a solvent molecule. Hydrates are a special form of solvates in which coordination occurs with water. Within the scope of the present disclosure, the solvate is preferably a hydrate.
The term "crystal" refers to the various solid forms formed by the compounds described herein, including crystalline forms and amorphous forms.
The term "hydrocarbyl" refers to alkyl or alkenyl.
The term "alkyl" refers to a linear, branched or cyclic saturated substituent consisting of carbon and hydrogen. It has preferably 1 to 20 carbon atoms, more preferably 1 to 12 carbon atoms. The term "alkyl" refers to a linear, branched or cyclic saturated hydrocarbyl group. The alkyl group specifically includes, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, cyclobutyl, n-pentyl, isopentyl, neopentyl, cyclohexyl, n-hexyl, isohexyl, 2,2,-methylbutyl and 2,3-dimethylbutyl, 16-alkyl, 18-alkyl. The term"C 1 - 2 0 alkyl" refers to a linear, branched or cyclic saturated
hydrocarbyl group containing 1 to 20 carbon atoms. When an alkyl group is substituted, the substituent may substitute at any available attachment point, and the substitution may be mono-substitution or poly-substitution. For example, the substituent can be selected from alkyl, alkenyl, alkoxy, alkylthio, alkylamino, deuterum, halogen, thiol, hydroxy, nitro, carboxy, ester, cyano, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio or oxo.
The term "alkenyl" refers to a linear, branched or cyclic unsaturated hydrocarbyl group containing a double bond, preferably containing 2 to 20 carbon atoms, more preferably 2 to 12 carbon atoms. When it is substituted, the substituent may substitute at any available attachment point, and the substitution may be mono-substitution or poly-substitution. For example, the substituent can be selected from alkyl, alkenyl, alkoxy, alkylthio, alkylamino, deuterum, halogen, thiol, hydroxy, nitro, carboxy, ester, cyano, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio or oxo.
The term "cycloalkyl" refers to a saturated monocyclic cyclohydrocarbyl group. A single ring generally includes 3 to 10 carbon atoms. Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl and
the like. In the present disclosure, spiro cycloalkyl groups, fused cycloalkyl groups, and bridged cycloalkyl groups are collectively referred to as polycyclic cycloalkyl groups.
The term "ring", unless otherwise specified, means any cyclic structure, and is not limited to any form and composition, and may be any form of a monocyclic ring, a bridged ring, a spiro ring, a fused ring, and a polycyclic ring, and may be a carbocyclic or heterocyclic ring or other forms of rings, such as a carbocyclic ring interrupted by carbonyl, and may be unsubstituted or substituted. When referring to "a ring containing a particular atom or group" means that the particular atom or group is part of the ring itself. For example, "the sixth ring contains C=O" means that the constituent group of the ring itself constituting the sixth ring contains C=O, and if only the substituent on the ring contains C=O, it is not among them.
The term "carbocyclyl" or "carbocyclic ring" refers to a carbocyclic group having 3 to 20 carbon atoms, preferably 3 to 16 carbon atoms, more preferably 4 to 12 carbon atoms, and includes cycloalkyl, cycloalkenyl, aryl, bicyclic carbocyclyl, polycyclic carbocyclyl, and the like. The term "heterocyclyl" or "heterocyclic ring" means that the ring structurally contains at least one heteroatom, and may specifically be, for example, heteroaryl, non-aromatic heterocyclyl, bicyclic heterocyclyl and polycyclic heterocyclyl containing one or more identical or different heteroatoms selected from 0, S and N, etc..
The term "aryl" is to be understood broadly and includes not only carbocyclic aryl but also heteroaryl.
The term "carbocyclic aryl" refers to a 6- to 10- membered all-carbon monocyclic or polycyclic aromatic group, including phenyl, naphthyl, biphenyl, and the like. The carbocyclic aryl group can be substituted or unsubstituted. The substituent is independently selected from alkyl, cycloalkyl
(such as cyclopropyl, cyclobutyl, cyclopentyl, etc.), alkenyl, azide, amino, deuterium, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, alkylsilyl and so on.
The term "heteroaryl" refers to a group of a heteroaromatic system containing 1 to 10 heteroatoms, including monocyclic aryl and fused-ring aryl. Heteroatoms include oxygen, sulfur, nitrogen, phosphorus, and the like. Wherein monoheterocyclic groups include, but not limited to, furan, thiophene, pyrrole, thiazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,3-thiadiazole, oxazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, tetrahydrofuran, tetrahydropyrrole, piperidine, piperazine, morpholine, isoxazolin, and the like. Fused heterocyclic groups include, but not limited to, quinoline, isoquinoline, indole, benzofuran, benzothiophene, purine, acridine, carbazole, fluorene, chromenone, fluorenone, quinoxaline, 3, 4-dihydronaphthalenone, dibenzofuran, hydrogenated dibenzofuran, benzoxazolyl, and the like. Heteroaryl groups can be substituted or unsubstituted. The substituent is, for example, selected from alkyl, cycloalkyl (such as cyclopropyl, cyclobutyl, cyclopentyl, etc.), alkenyl, azide, amino, deuterium, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, alkylsilyl and so on.
The term "hydrogen", when not specifically stated, includes all isotopes of hydrogen, specifically can be protium (H), deuterium (D) or tritium (T), and preferably, hydrogen at different positions is independently selected from protium or deuterium. Wherein, the "hydrogen" in the active hydrogen position is protium. The term "deuterium" is an isotope of protium, the atomic mass is twice of that of the latter, and the binding to carbon is stronger.
"Deuterated" and "deuterium" means that protium is replaced with deuterium at the specified position.
The term "haloalkyl" refers to an alkyl group substituted by at least one halogen atom.
The term "heterocyclic group" means a cyclic group containing at least one hetero atom, wherein the hetero atom is nitrogen, oxygen, sulfur, and the like. The heterocyclic groups include monoheterocyclic groups and polyheterocyclic groups.
The term "heteroatom", when not specifically indicated, generally includes nitrogen, oxygen and sulfur.
The term "halogen", when not specifically indicated, generally includes fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine, and further preferably fluorine.
The term "plurality", "multiple" or "more", when used to define the number of substituents or interrupting atoms/groups, generally does not exceed the number of chemically replaceable groups or the number of bonds that can be interrupted, more specifically, "plurality", "multiple" or "more" preferably refers to a number less than or equal to 6, more preferably less than or equal to 5, and further preferably less than or equal to 4.
The term "optional" or "optionally" comprises two parallel schemes, "selected" and "not selected". For example, "the sixth ring optionally contains C=O1 means that the sixth ring contains C=O or does not contain C=O.
Detailed Description of Exemplary Embodiments
The following embodiments are intended to provide a more complete
understanding of the present disclosure, and are not intended to limit the present disclosure in any way. The structures of all compounds were determined by 'H NMR or MS.
The compound names used in the embodiments are abbreviated as follows: DCM: dichloromethane; EA: ethyl acetate; DMF: dimethylformamide; THF: tetrahydrofuran; TEA: triethylamine T3P: 1-propylphosphoric anhydride; Boc-hydrazine: tert-butoxycarbonyl hydrazine; HATU: 2-(7-oxobenzotriazole)-N,N,N',N'-tetramethyluron hexafluorophosphate TFA: trifluoroacetic acid DMA: N,N-dimethylacetamide DPPP: 1,3-bis(diphenylphosphino)propane DPPA: diphenylphosphoryl azide DBU: 1,8-diazabicyclo-bicyclo(5,4,0)-7-undecene DIPEA: N,N-diisopropylethylamine
The present disclosure will be further described below in conjunction with specific embodiments: Embodiment 1: Preparation of Compound I-1 OBn O OBn O OBn O OBnO
On OH : On O H 2 N' Boc 0 O aq.NaOHO OoH 2 N 0 l OH 0 2N. 0" aqN0Y`-T _
la lb 1c 1d OH
OBn 0 OBnO 0 OBn 0 O n TFA OP HCHO O 1i 0- 1 N A ~N N" S (1!1 NH H 1N NHBoc OC2 'H N H if 1g 1h
OBnO OH
S S ij 1-1
Preparation of Compound 1b: In 20 mL DMF, Compound la (2.0 g, 8.1 mmol), DBU (1.85 g, 12.2 mmol) and ethyl iodide (2.28 g, 14.6 mmol) were reacted at room temperature for 16 hours. Then the mixture was diluted with 100 mL water, and extracted with EA. The organic phases were combined, washed sequentially with sodium thiosulfate, 0.5N HCl and brine, dried over anhydrous sodium sulfate, and then concentrated to give 2.1 g oily product, i.e., Compound lb.
Preparation of Compound lc: In N,N-dimethylacetamide (20 mL), Compound lb (2.1 g, 7.7 mmol), Boc-hydrazine (1.53g, 11.6mmol) and pyridinium p-toluenesulfonate (5.78 g, 23.1 mmol) were reacted at 60 °C for 16 hours. After the reaction finished, the mixture was added with 100 mL water, and then extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate and concentrated to give a crude product, which was purified by column chromatography to give 1.9 g yellow oily product, i.e., Compound Ic. ESI-MS m/z 389.2 (M+H)*
Preparation of Compound Id: Compound I (1.9 g, 4.9 mmol) was dissolved in 10 mL ethanol, and IN aq. NaOH solution (14.7 mL, 14.7 mmol) was added, and then the mixture was reacted at 60 °C for 24 hours. The mixture was acidified with 3N HCl and extracted with DCM. The organic phases were combined, washed with brine, dried and concentrated. The crude product was triturated in dichloromethane/petroleum ether (5 mL/50 mL) to give 1.1 g white solid, i.e., Compound Id. ESI-MS m/z 361.2 (M+H)*
Preparation of Compound If: In DCM, Compound Id (360 mg, 1 mmol), Compound le (133 mg, 1.2 mmol), TEA (303 mg, 3.0 mmol) and HATU (570 mg, 1.5 mmol) were stirred at room temperature overnight, then diluted with water, and extracted with DCM. The organic phases were combined, washed with brine, dried and concentrated, and purified by column chromatography to give 350 mg white solid, i.e., Compound If. ESI-MS m/z 454.2 (M+H)*
Preparation of Compound Ig: Compound If (350 mg, 0.77 mmol) was dissolved in 4 mL DCM, added with 1 mL TFA, and reacted at 0 °C for 6 hours. The mixture was concentrated, and IN NaOH was added till basic, and the mixture was extracted with DCM/iPrOH. The organic phases were combined, washed with brine, dried and concentrated to give 210 mg oily product, which was directly used in the next step.
Preparation of Compound Ih: Compound ig (210 mg, 0.59 mmol) was dissolved in 5 mL toluene. 30 mg paraformaldehyde and 100 mg acetic acid was added, and the mixture was reacted at 100 °C for 3 hours. The mixture was concentrated and separated by thin layer chromatography to give 145 mg product. ESI-MS m/z 366.2 (M+H)*
Preparation of Compound lj: Compound 1h (140 mg, 0.38 mmol) and Compound li (114 mg, 0.5 mmol) were reacted in a solution of T3P in ethyl acetate at 100 °C for 3 hours in a pressured reactor. The mixture was cooled, diluted with saturated NaHCO 3, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by silica gel plate to give 170 mg product. ESI-MS m/z 576.2 (M+H)*.
Preparation of Compound I-1: In 5 mL DMA, Compound ij (170 mg, 0.29 mmol) and lithium chloride (50 mg, 1.18 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water,
and added with 2N hydrochloric acid to adjust pH to 5-6. The mixture was filtered, and the solid was dried under vacuum to give 120 mg product. 'HNMR (400MHz, CDC 3) 6: 7.46-7.53(m, 2H), 7.36 (s, 2H), 7.13-7.17(m, 3H), 6.89(s, 1H), 6.76(s, 1H), 5.76-5.88(m, 2H), 5.14(s, 1H), 4.88-4.91(m, 1H), 4.77-4.80(m, 1H), 4.48-4.51(m, 1H), 3.66-3.69(m, 1H), 2.30(s, 2H), 2.16(s, 2H), 1.78-1.90(m, 6H); ESI-MS m/z 486.2 (M+H)*.
Embodiment 2: Preparation of Compound I-5 OH OBnl 0&C OH 0 C OBn F, T3P - N" C N F (2a) N N Lz N~z N -
1h 2b 1-5
Preparation of Compound 2b: Compound 1h (180 mg, 0.49 mmol) and Compound 2a (264 mg, 1.0 mmol) were reacted in a solution of T3P in ethyl acetate at 100 °C for 3 hours in a pressured reactor. The mixture was cooled, diluted with saturated NaHCO 3 aqueous solution, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by silica gel plate to give 190 mg product. ESI-MS m/z 612.2 (M+H)*.
Preparation of Compound 1-5: In 5 mL DMA, Compound 2b (190 mg, 0.31 mmol) and lithium chloride (50 mg, 1.18 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 5-6. The mixture was filtered, and the solid was dried under vacuum to give 136mg product. 1 HNMR (400MHz, CDCl3) 6: 7.04-7.12(m, 3H), 7.00-7.02(d, 1H, J=7.6 Hz), 6.90-6.93(m, 1H), 6.79-6.83(m, 1H), 6.63-6.64(d, 1H, J=7.2 Hz), 5.74-5.76(d, 1H, J=7.6 Hz), 5.42-5.46(m, 1H), 5.06(s, 1H), 4.82-4.86(m, 1H), 4.69-4.77(m, 1H), 4.37-4.40(m, 1H), 4.04-4.07(m, 1H), 2.18-2.28(m, 2H), 2.06-2.09(m, 2H), 1.74-1.85(m, 6H); ESI-MS m/z (M+H)* 522.2.
Embodiment 3: Preparation of Compound 1-7 0 0 0a
3a 3b 3c 3d OBn 0 OBn 0 OBn O HCIOOH OH NNH HCI (3g) O H - H CbzHN OA 0N ,H H 'NH NN_,, 2 3e 3f 3h 3I
OBn O OH 0 N O On OO N N
F 3k 1-7
Preparation of Compound 3b: Compound 3a (5.0 g, 27.8 mmol) was added to n-butyl vinyl ether (10 mL), then added with palladium trifluoroacetate (100 mg, 0.3 mmol), triethylamine (3.03 g, 30 mmol) and DPPP (124 mg, 0.3 mmol), and stirred at 75 °C overnight in a pressured reactor. TLC showed the reaction was complete. The mixture was added with 50 mL water and extracted with ethyl acetate twice, and the organic phase was washed with brine, dried over anhydrous sodium sulfate, concentrated and separated by column chromatography to give 4.8 g product, which was directly used in the next step.
Preparation of Compound 3c: Compound 3b (4.8 g, 23.3 mmol) was dissolved in 50 mL anhydrous toluene, and added with IN diethylzinc solution (70 mL, 70 mmol) at -40 °C under nitrogen protection. After addition, the mixture was stirred for 1 hour, and then added with chloroiodomethane (8.22 g, 46.6 mmol). After addition, the mixture was stirred for 2 hours, slowly heated to room temperature and stirred overnight. TLC showed the reaction was complete, and then the reaction mixture was poured into ammonium chloride solution, and then extracted with ethyl acetate (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated
to give 4.9 g crude product.
Preparation of Compound 3d: Intermediate 3c (4.9 g, 22.2 mmol) was dissolved in 50 mL methanol, added with aqueous sodium hydroxide, and stirred at room temperature for 5 hours. TLC showed starting materail consumed. HCl was added to adjust pH = 2-3 and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were concentrated to give 2.3 g crude product.
Preparation of Compound 3e: Compound 3d (2.3 g, 17.7 mmol) was dissolved in 15 mL toluene, added with DPPA (5.84 g, 21.2 mmol) and TEA (3.58 g, 35.4 mmol), stirred at room temperature for 2 hours, then added with benzyl alcohol (5.73 g, 53.1 mmol), and reacted at 90 °C for 2 hours. TLC showed the reaction was complete, and the mixture was cooled to room temperature, and added with 100 mL water to quench the reaction, extracted with ethyl acetate (80 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which ran through column chromatography to give 1.5 g mixture of product and benzyl alcohol that directly used in the next step.
Preparation of Compound 3f: 1.5 g crude of Compound 3e was dissolved in 10 mL methanol, and added with 150 mg Pd/C and 0.2 mL concentrated hydrochloric acid. The mixture was replaced with hydrogen for three times and was reacted for 5 hours. TLC showed the reaction was complete, and the mixture was filtered through diatomite, and the filtrate was added with HCl to adjust pH = 1-2, and concentrated to dry to give 0.6 g product, which was directly used in the next step.
Preparation of Compound 3h: In 15 mL dichloromethane, Compound 3f (0.6 g, 4.36 mmol), Compound 3g (1.12 g, 4.0 mmol), HATU (1.82 g, 4.8 mmol) and TEA (1.21 g, 12.0 mmol) were stirred at room temperature over night. TLC
showed the reaction was complete, and the mixture was added with 20 mL water and extracted with dichloromethane (30 mL x 2), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 0.85 g product.
Preparation of Compound 3i: In 5 mL DMF, Compound 3h (0.85 g, 2.6 mmol), potassium carbonate (718 mg, 5.2 mmol) and 2,4-dinitrophenylhydroxylamine (0.78 g, 3.9 mmol) were stirred at room temperature for 5 hours. TLC showed the reaction was complete, and the mixture was added with 20 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 0.73g product.
Preparation of Compound 3j: Compound 3i (0.73 g, 2.1 mmol), acetic acid (120 mg, 2.1 mmol) and paraformaldehyde (0.23g, 2.52mmol) were refluxed in toluene for 2 hours. TLC showed the reaction was complete. The mixture was concentrated, and the residue was added with 10 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 0.45g product.
Preparation of Compound 3k: In 3mL solution of T3P in ethyl acetate, Compound 3j (450 mg, 1.27 mmol) and Compound 2a (660 mg, 2.54 mmol) were reacted at 100 °C for 3 hours in a pressured reactor. The mixture was cooled, diluted with saturated NaHCO 3, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by column chromatography to give 290 mg product. ESI-MS m/z 602.2 (M+H)*.
Preparation of Compound 1-7: In 5 mL DMA, Compound 3k (290 mg, 0.48 mmol) and lithium chloride (50 mg, 1.18 mmol) were reacted at 100 °C for 3
hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 5-6. The mixture was filtered, and the solid was dried under vacuum to give 187mg product. 'HNMR (400MHz, CDCl3) 6: 7.05-7.15(m, 3H), 7.00-7.02(d, 1H, J=8.0 Hz), 6.94-6.98(m, 1H), 6.81-6.85(m, 1H), 6.65-6.67(d, 1H, J=8.0 Hz), 5.80-5.82(d, 1H, J=8.0 Hz), 5.38-5.42(m, 1H), 5.13(s, 1H), 4.96-5.00(m, 1H), 4.21-4.27(m, 2H), 4.02-4.06(m, 1H), 3.61-3.67(m, 2H), 3.22-3.25(m, 1H), 2.84-2.91(m, 1H), 0.44-0.47(m, 4H); ESI-MS m/z (M+H)* 512.2.
Embodiment 4: Preparation of Compound 1-8 Br0 N S3g OBn 0 HO ^_SH B V H2 Sg o
4a 4b 4c 4d 4e
OBn O OH 0 0---- W '' 0 -,, OBn 0 OBn 0 2a O. N 1:,N..N V
'. -- N '-1 F'NY'~ N ~N H H:N)X 'IV F F
4f 4g 4h F 1-8
Preparation of Compound 4b: In 30mL dimethyl sulfoxide, Compound 4a (2.24g, 28.7 mmol), bromocyclopropane (3.47g, 28.7 mmol) and potassium t-butoxide (3.22g, 28.7 mmol) were reacted at 80 °C overnight. The mixture was cooled to room temperature, and added with saturated NaHCO 3 solution to quench the reaction, and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with brine, dried and concentrated to give 2.8 g yellow liquid. It was directly used in the next step.
Preparation of Compound 4c: In 20 mL tetrahydrofuran, Compound 4b (1.60g, 13.6 mmol), phthalimide (2.39 g, 16.2 mmol), triphenylphosphine (5.34 g, 20.4 mmol) and isopropyl azodicarboxylate (4.12 g, 20.4 mmol) were reacted at room temperature overnight. The mixture was added with water to quench the reaction, and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with brine, dried and concentrated to give a crude
product, which was separated by column chromatography to give 2.4 g oily product. It was directly used in the next step.
Preparation of Compound 4d: Compound 4c (2.40 g, 10 mmol) was dissolved in 30 mL methanol, 2 g hydrazine hydrate was added, and then the mixture was reacted at 75 °C for 2 hours. TLC showed the reaction was complete. The mixture was cooled and filtered. The filtrate was concentrated and triturated with ethyl ether. The mixture was filtered, and the filtrate was dried to give 1.04 g crude product. It was directly used in the next step.
Preparation of Compound 4e: In 10 mL dichloromethane, Compound 4d (420 mg, 3.6 mmol), Compound 3g (864 mg, 2.4 mmol), HATU (1.37 g, 3.6 mmol) and TEA (720 mg, 7.2 mmol) were stirred at room temperature over night. TLC showed the reaction was complete, and the mixture was added with 30 mL water and extracted with dichloromethane (30 mL x 2), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by silica gel plate to give 900 mg product. ESI-MS m/z (M+H)* 344.1.
Preparation of Compound 4f: In 5 mL DMF, Compound 4e (900 mg, 2.4 mmol), potassium carbonate (1.08 g, 7.8 mmol) and 2,4-dinitrophenylhydroxylamine (780 mg, 3.9 mmol) were stirred at 60 °C for 5 hours. The mixture was added with 20 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by silica gel plate to give 120 mg product.
Preparation of Compound 4g: Compound 4f (120 mg, 0.33 mmol), acetic acid (36 mg, 0.06 mmol) and paraformaldehyde (100 mg, 1.1 mmol) were refluxed in toluene for 6 hours. The mixture was concentrated, and the residue was
added with 10 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by silica gel plate to give 85 mg product.
Preparation of Compound 4h: In 2mL solution of T3P in ethyl acetate, Compound 4g (85 mg, 0.23 mmol) and Compound 2a (90 mg, 0.34 mmol) were reacted at 100 °C for 3 hours in a pressured reactor. The mixture was cooled, diluted with saturated sodium bicarbonate, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by column chromatography to give 20 mg product.
Preparation of Compound 1-8: In 1 mL DMA, Compound 4h (20 mg, 0.03 mmol) and lithium chloride (50 mg, 1.18 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 3-4. The mixture was filtered, and the solid was dried under vacuum to give 5mg product. 1 HNMR (400MHz, CDCl3) 6: 7.02-7.12(m, 5H), 6.85(m, 1H), 6.77(m, 1H), 5.81(d, 1H, J=7.6 Hz), 5.43(m, 1H), 5.20(s, 1H), 5.10(d, 1H, J=12.8 Hz), 4.25(d, 1H, J=12.8 Hz), 4.06(d, 2H, J=14 Hz), 3.31(m, 1H), 2.73(t, 2H, J=6.8 Hz), 1.95 (m, 1H), 0.89 (m, 2H), 0.56(m, 2H); ESI-MS m/z (M+H)* 528.1.
Embodiment 5: Preparation of Compound 1-14 OB OBn 0 OBnO OBnO OBn O C O N"O TFA O HCHO O Ho O .NON + >-NH 2 HATU ' N,NH H NHBoc 1d 5a 5b 5c 5d
OH OBn O OH 0
F a) \/ ,T3P O . S .. 2a __ N N
F F F 5e F 1-14
Preparation of Compound 5b: In DCM, Compound Id (360 mg, 1 mmol), Compound 5a (116 mg, 1.2 mmol), TEA (303 mg, 3.0 mmol) and HATU (570
mg, 1.5 mmol) were stirred at room temperature overnight, then diluted with water, and extracted with DCM. The organic phases were combined, washed with brine, dried and concentrated, and separated by column chromatography to give 320 mg white solid.
Preparation of Compound 5c: Compound 5b (320 mg, 0.73 mmol) was dissolved in 4 mL DCM, added with 1 mL TFA, and reacted at 0 °C for 6 hours. The mixture was dried, added with IN NaOH to adjust to be alkaline, and extracted with DCM/iPrOH. The organic phases were combined, washed with brine, dried and concentrated to give 195mg oily product, which was directly used in the next step.
Preparation of Compound 5d: Compound 5c (195 mg, 0.57 mmol) was dissolved in 5 mL toluene, added with 30 mg paraformaldehyde and 100 mg acetic acid, and reacted at 100 °C for 3 hours. The mixture was concentrated and separated by thin layer chromatography to give 130mg product.
Preparation of Compound 5e: In a solution of T3P in ethyl acetate, Compound 5d (130 mg, 0.37 mmol) and Compound 2a (114 mg, 0.5 mmol) were reacted at 100 °C for 3 hours in a pressured reactor. The mixture was cooled, diluted with saturated sodium bicarbonate, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by silica gel plate to give 130mg product.
Preparation of Compound 1-14: In 1 mL DMA, Compound 5e (130 mg, 0.23 mmol) and lithium chloride (50 mg, 1.18 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 3-4. The mixture was filtered, and the solid was dried under vacuum to give 35mg product. 1 HNMR (400MHz, CDCl3) 6: 7.03-7.11(m, 4H), 6.94(m, 1H), 6.82(m, 1H), 6.67(m,
1H), 5.78(d, 1H, J=7.6 Hz), 5.43(d, 1H, J=12.8 Hz), 5.19(t, 1H, J=7.6 Hz), 5.12(s, 1H), 4.93(d, 1H, J=13.2 Hz), 4.56(d, 1H, J=13.6 Hz), 4.08(d, 1H, J=14 Hz), 2.24(m, 1H), 2.13 (m, 3H), 0.54(t, 2H, J=8.0 Hz), 0.34 (m, 2H); ESI-MS m/z (M+H)* 508.2.
With the same way, the following compounds were synthesized: LCMS Compound Structure ([M+H]) Purity OH 0
1-9 N'N 472.2 96%
OH 0 0-00
1-10 N ~ ~488.2 93%
OH 0
1-21 F 'N" 504.2 95%
Embodiment 6: Preparation of Compound 1-65 OBn 0 On0OBnO0
N O N 2a NOnO
6a 6b 6c 6d
OBn 0 OH 0 0 1 N101
F F 6e 1-65
Preparation of Compound 6b: In 5 mL dichloromethane, Compound 6a (600 mg, 2.13 mmol), Compound 3g (280 mg, 2.34 mmol), HATU (1.21 g, 3.20 mmol) and TEA (850 mg, 8.5 mmol) were stirred at room temperature over night. TLC showed the reaction was complete, and the mixture was added with
20 mL water and extracted with dichloromethane (30 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 455mg product.
Preparation of Compound 6c: In 15 mL DMF, Compound 6b (455 mg, 1.46 mmol), potassium carbonate (543 mg, 4.38 mmol) and 2,4-dinitrophenylhydroxylamine (392 mg, 2.19 mmol) were stirred at room temperature for 16 hours. TLC showed the reaction was complete, and the mixture was added with 20 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by silica gel plate to give 200mg product. ESI-MS m/z (M+H)* 326.1
Preparation of Compound 6d: Compound 6c (200 mg, 0.62 mmol), acetic acid (200 mg, 3.3 mmol) and paraformaldehyde (18 mg, 0.62 mmol) were refluxed in 10 mL toluene for 2 hours. TLC showed the reaction was complete. The mixture was concentrated, and the residue was added with 10 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 190mg product. ESI-MS m/z (M+H)* 338.1
Preparation of Compound 6e: In 3 mL solution of T3P in ethyl acetate, Compound 6d (190 mg, 0.56 mmol) and Compound 2a (223 mg, 0.84 mmol) were reacted at 100 °C for 1.5 hours in a pressured reactor. The mixture was cooled, diluted with water, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by silica gel plate to give 227mg product.
Preparation of Compound 1-65: In 5 mL DMA, Compound 6e (227 mg, 0.4
mmol) and lithium chloride (86 mg, 2.0 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 5-6. The mixture was filtered, and the solid was dried under vacuum to give 100mg product. 'HNMR (400MHz, CDC 3) 6: 7.10 (m, 3H), 6.99(m, 2H), 6.84(m, 1H), 6.70(m, 1H), 5.75(d, 1H, J=7.6 Hz), 5.40(d, 1H, J=15.2), 5.14(s, 1H), 4.82(d, 1H, J=12.8 Hz), 4.25(d, 1H, J=12.8 Hz), 4.04(d, 1H, J=14.0 Hz), 3.76(m,3H), 2.98(m, 2H), 2.54(s, 1H), 2.05-2.15(m, 6H); ESI-MS m/z (M+H)*494.1.
Embodiment 7: Preparation of Compound 1-66 0 OBna F OBno0 F OBnO0
F-K<a)NH F N22 HCI -p--' O HN F 0 O HN N ' 2a OF 2 Lz NH NNH2 H 7a 7b 7c 7d
OBn F O F
7e 1-66
Preparation of Compound 7b: In 10 mL dichloromethane, Compound 7a (250 mg, 1.82 mmol), Compound 3g (465 mg, 1.65 mmol), HATU (941 mg, 2.48 mmol) and TEA (660 mg, 6.6 mmol) were stirred at room temperature over night. TLC showed the reaction was complete, and the mixture was added with 20 mL water and extracted with dichloromethane (30 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 430mg product.
Preparation of Compound 7c: In 15 mL DMF, Compound 7b (430 mg, 1.30 mmol), potassium carbonate (538 mg, 3.9 mmol) and 2,4-dinitrophenylhydroxylamine (391 mg, 1.96 mmol) were stirred at room temperature for 16 hours. TLC showed the reaction was complete, and the mixture was added with 20 mL water and extracted with dichloromethane (20
mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by silica gel plate to give 220mg product. ESI-MS m/z (M+H)* 344.1
Preparation of Compound 7d: Compound 7c (220 mg, 0.64 mmol), acetic acid (200 mg, 3.3 mmol) and paraformaldehyde (20 mg, 0.64 mmol) were refluxed in 10 mL toluene for 2 hours. TLC showed the reaction was complete. The mixture was concentrated, and the residue was added with 10 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by silica gel plate to give 165mg product. ESI-MS m/z (M+H)*356.1
Preparation of Compound 7e: In 3 mL solution of T3P in ethyl acetate, Compound 7d (165 mg, 0.46 mmol) and Compound 2a (184 mg, 0.70 mmol) were reacted at 100 °C for 1.5 hours in a pressured reactor. The mixture was cooled, diluted with water, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by silica gel plate to give 100mg product.
Preparation of Compound 1-66: In 3 mL DMA, Compound 7e (100 mg, 0.17 mmol) and lithium chloride (35 mg, 0.83 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 5-6. The mixture was filtered, and the solid was dried under vacuum to give 45mg product. 1 HNMR (400MHz, CDC 3) 6: 7.11 (m, 3H), 6.96(m, 1H), 6.82(m, 1H), 6.63(m, 1H), 5.98(d, 1H, J=9.2 Hz), 5.39(m, 1H), 5.02-5.12(m, 2H), 4.23(d, 1H, J=12.8 Hz), 4.06(d, 1H, J=14.0 Hz), 2.39-2.49(m, 5H); ESI-MS m/z (M+H)* 512.1
Embodiment 8: Preparation of Compound 1-77
On0OBnO0 OBn 0
C 3g OO HO N 2a NH 2 N ~NHN NN
8a 8b 8c 8d
OBn 0 OH 0 Z N N N
8e 1-77
Preparation of Compound 8b: In 10 mL dichloromethane, Compound 8a (250 mg, 2.5 mmol), Compound 3g (705 mg, 2.5 mmol), HATU (1.19 g, 3.1 mmol) and TEA (1.01 g, 10.5 mmol) were stirred at room temperature over night. TLC showed the reaction was complete, and the mixture was added with 20 mL water and extracted with dichloromethane (30 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 780mg product.
Preparation of Compound 8c: In 10 mL DMF, Compound 8b (780 mg, 2.5 mmol), potassium carbonate (1.04 g, 7.5 mmol) and 2,4-dinitrophenylhydroxylamine (752 mg, 3.8 mmol) were stirred at room temperature for 16 hours. TLC showed the reaction was complete, and the mixture was added with 20 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by silica gel plate to give 390mg product. ESI-MS m/z (M+H)* 326.1
Preparation of Compound 8d: Compound 8c (390 mg, 1.2 mmol), acetic acid (500 mg, 8.3 mmol) and paraformaldehyde (36 mg, 1.2 mmol) were refluxed in 10 mL toluene for 2 hours. TLC showed the reaction was complete. The mixture was concentrated, and the residue was added with 10 mL water and extracted with dichloromethane (20 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was
separated by silica gel plate to give 280mg product. ESI-MS m/z (M+H)*338.1
Preparation of Compound 8e: In 1.5 mL solution of T3P in ethyl acetate, Compound 8d (99 mg, 0.30 mmol) and Compound 2a (117 mg, 0.45 mmol) were reacted at 100 °C for 1.5 hours in a pressured reactor. The mixture was cooled, diluted with water, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by silica gel plate to give 150mg product.
Preparation of Compound 1-77: In 3 mL DMA, Compound 8e (150 mg, 0.26 mmol) and lithium chloride (70 mg, 1.66 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 5-6. The mixture was filtered, and the solid was dried under vacuum to give 75mg product. 1 HNMR (400MHz, CDCl3) 6: 7.13-7.14(m, 3H), 7.1-7.03(d, 2H, J=8.0), 6.84-6.88(m, 1H), 6.70-6.72(d, 1H, J=8.0), 5.81-5.83(d, 1H, J=8.0), 5.42-5.44(m, 1H), 5.15(s, 1H), 4.84-4.87(m, 1H), 4.29-4.32(m, 1H), 4.06-4.09(m, 1H), 2.09-2.19(m, 7H); ESI-MS m/z (M+H)* 494.1
With the same way, the following compounds were synthesized: LCMS Compound Structure ([M+H]*) Purity OH 0
1-69 N'N 458.2 95%
OH 0 Ot, N
1-81 'N 476.1 94%
OH 0
1-83 N, 476.2 97
1-85 F NN 476.2 97
OH 0
1-89 N N 492.1 96% -S
Embodiment 9: Preparation of Compound11-5
H 2 NOH OH O O HN O d HC I/ H2N7 0 - 0 0 9a 9b 9c 9d
OBn O OH 0 OBn OBn0 0 N NO> 0 NNk' 1 0H 0 NN> 2 N '0 kzN N k-' 1NN 0 0 NHBoc HF F
9e 9f F 9g F 11-5
Preparation of Compound 9b: In a mixed solvent of DMF (7.5 ml) and toluene (7.5 ml), Compound 9a (250 mg, 2.02 mmol), phthalic anhydride (300 mg, 2.02 mmol), triethylamine (408 mg, 4.04 mmol) were reacted at 130 °C for 5 hours, and TLC showed the reaction was completed, and the mixture was added with water and stirred for 1 hour, and filtered to give 332 mg white solid, which was directly used in the next step.
Preparation of Compound 9c: Compound 9b (332 mg, 1.53 mmol) and bromoacetaldehyde dimethyl acetal (517 mg, 3.06 mmol) were dissolved in 15 ml DMA, heated to 40 °C, and then added with sodium tert-butoxide (294 mg, 3.06 mmol), and the mixture was stirred at 40 °C for 5 hours. The mixture was
cooled to room temperature, added with 10 mL water to quench the reaction, added with glacial acetic acid to adjust pH = 3-4, extracted with ethyl acetate, dried, concentrated, and separated by column chromatography to give 265 mg product.
Preparation of Compound 9d: Compound 9c (265 mg, 0.87 mmol) was dissolved in 30 mL methanol, 2 g hydrazine hydrate was added, and then the mixture was reacted at 75 °C for 2 hours. TLC showed the reaction was complete. The mixture was cooled and filtered. The filtrate was concentrated and triturated with ethyl ether. The mixture was filtered, and the filtrate was dried to give 96mg crude product. It was directly used in the next step.
Preparation of Compound 9e: In DCM, Compound Id (137 mg, 0.38 mmol), Compound 9d (96 mg, 0.55 mmol), TEA (115 mg, 1.14 mmol) and HATU (289 mg, 0.76 mmol) were stirred at room temperature overnight, then diluted with water, and extracted with DCM. The organic phases were combined, washed with brine, dried and concentrated, and separated by column chromatography to give 155mg product.
Preparation of Compound 9f: Compound 9e (155 mg, 0.3 mmol) was added with 18 mL acetonitrile and 3 mL water, and the mixture was heated to 60 °C, dropwise added with methanesulfonic acid (8 mg, 0.9 mmol) and reacted for 6h. TLC showed the reaction was complete. The mixture was added with sodium bicarbonate aqueous solution to be weakly alkaline, concentrated and extracted with dichloromethane, and the organic phases were combined, dried, concentrated and separated by silica gel plate to give 60 mg white solid.
Preparation of Compound 9g: In a solution of T3P in ethyl acetate, Compound 9f (60 mg, 0.17 mmol) and Compound 2a (69 mg, 0.26 mmol) were reacted at 100 °C for 3 hours in a pressured reactor. The mixture was cooled, diluted
with saturated NaHCO 3, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by chiral column to give 15 mg product.
Preparation of Compound 11-5: In 1 mL DMA, Compound 9g (15 mg, 0.025 mmol) and lithium chloride (10 mg, 0.24 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 3-4. The mixture was filtered, and the solid was dried under vacuum to give 5mg product. 1 HNMR (400MHz, CDCl3) 6: 7.28-7.34(m, 1H), 7.09-7.16(m, 2H), 6.83-7.01(m, 2H), 6.66-6.68(d, 1H, J=8.0); 6.56-6.59(m, 1H), 5.77-5.90(m, 1H), 5.28-5.37(m, 1H), 5.02-5.18(m, 1H), 4.61-4.71(m, 1H), 3.91-4.17(m, 3H), 3.59-3.68(m, 1H), 2.95-3.07(m, 1H), 0.23-0.89(m, 4H); ESI-MS m/z (M+H)* 510.1.
With the same way, the following compounds were synthesized: LCMS Compound Structure ([M+H]) Purity
OOH 0 N 11-1 NO 474.2 95%
OH 0 OCH,
11-8 N O 528.1 94% F - /
0 OH O
II-9 N O 492.1 940
OH 0 N
11-13 N o 492.1 95% F S
OH 0
11-17 F 492.1 96%
Embodiment 10: Preparation of Compound 11-6 OBn O OBn O N"JrU0- N Ny` N .HBoc N NH2 1c 10a
OBn O
10b loc 10d 10e lOf
OBn 0 OH 0 OBn NNO N0N
N 2a NN N N'NJ-' 0 F H FOsFF FF / \ "
FF 10g 10h 11-6
Preparation of Compound 10a: Compound I (388 mg, 1 mmol) was dissolved in 3 mL dichloromethane and added with 1 mL trifluoroacetic acid, and the mixture was stirred at room temperature for 3 hours. TLC showed the reaction was complete, and the mixture was added with 3N sodium hydroxide solution to adjust pH = 9-10. The mixture was extracted with dichloromethane, and organic phases were combined, washed with brine, dried and concentrated to give 270 mg solid, which was directly used in the next step.
Preparation of Compound 10c: Compound 10b (1.0 g, 7.8 mmol) was dissolved in 10 mL anhydrous tetrahydrofuran and replaced with nitrogen for three times. The mixture was cooled to -78 °C and 2.5M n-butyllithium
solution (3.1 mL, 7.8mmol) was added slowly under nitrogen protection. After addition, the mixture was stirred at this temperature for 2 hours. Then allyl chloroformate (0.94 g, 7.8 mmol) was added by dropwise. After addition, the mixture was stirred at this temperature for 2 hours, and TLC showed the starting materials were completely reacted. The reaction mixture was poured into saturated ammonium chloride solution, and extracted with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated to give 1.65g oily product.
Preparation of Compound 10d: Compound 10c (1.65 g, 7.8 mmol) was dissolved in 15 mL anhydrous tetrahydrofuran, and 1M diisobutylaluminum hydride solution (11.7 mL, 11.7 mmol) was added slowly at -78 °C under nitrogen protection. After addition, the mixture was stirred at this temperature for 2 hours. TLC showed the starting materials were completely reacted. The reaction mixture was poured into saturated ammonium chloride solution, and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated to give 1.57g oily product.
Preparation of Compound 10e: Compound 10d (1.57 g, 7.4 mmol) was dissolved in 15 mL methanol, and p-toluenesulfonic acid monohydrate (140 mg, 0.74 mmol) was added. The mixture was stirred at room temperature overnight. TLC showed the starting materials were completely reacted. The mixture was added with saturated sodium bicarbonate solution till neutral, then concentrated. The residue was separated by column chromatography to give 0.86 g yellow oily product.
Preparation of Compound 10f: Compound 10a (270 mg, 0.94 mmol) and Compound 10e (255 mg, 1.13 mmol) were dissolved in 5 mL acetonitrile. Under nitrogen protection and at -20 °C, IM solution of tin tetrachloride in
dichloromethane (1.4 mL, 1.41 mmol) was added dropwise. After addition, the mixture was stirred at this temperature for 3 hours. The mixture was added with saturated sodium bicarbonate solution, stirred for 30 min, and seperated, The aqueous phase was extracted with dichloromethane. The organic phases were combined, washed with brine, dried and concentrated to give 428 mg crude product.
Preparation of Compound 10g: Compound 10f (428 mg, 0.89 mmol) was dissolved in 5 mL tetrahydrofuran, and tetrakis(triphenylphosphine)palladium (104 mg, 0.09 mmol) and morpholine (774 mg, 8.9 mmol) were added and reacted at room temperature for 2 hours. TLC showed the reaction was complete. The mixture was concentrated, and the residue was separated by column chromatography to give 216 mg product.
Preparation of Compound 10h: In 3mL solution of T3P in ethyl acetate, Compound lOg (216 mg, 0.61 mmol) and Compound 2a (242 mg, 0.92 mmol) were reacted at 100 °C for 3 hours in a pressured reactor. The mixture was cooled, diluted with saturated NaHCO 3, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by column chromatography to give 200 mg crude product, which was separated by chiral column to give 40 mg product.
Preparation of Compound 11-6: In 1 mL DMA, Compound 10h (40 mg, 0.067 mmol) and lithium chloride (20 mg, 0.48 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 3-4. The mixture was filtered, and the solid was dried under vacuum to give 25mg product. 1 HNMR (400MHz, CDC 3) 6: 7.05-7.15(m, 5H), 6.85(m, 1H), 6.70(d, 1H, J=7.6 Hz), 5.78(d, 1H, J=7.6 Hz), 5.3(m, 2H), 4.69(d, 1H, J=6.8 Hz), 4.17(d, 1H, J=14 Hz), 4.09 (d, 1H, J=14 Hz), 3.90 (m, 1H), 3.69 (m, 1H), 3.44 (d, 1H, J=15.2
Hz), 0.95 (m, 1H), 0.74 (m, 3H); ESI-MS m/z (M+H)* 510.1.
With the same way, the following compounds were synthesized:
Compound Structure MH+) Purity OH 0
11-2 N O 474.2 95%
OH 0 N 0 'W
II-7 N O 526.2 94% F
OH 0
11-10 N O 492.1 950 ° N F
OH 0
11-14 C N O8492.1 96% F S6
OH 0 )1
11-18 F N, NL::o 492.1 950
OH 0
11-22 Ci' 1N~ 508.1 96%o
OH 0 0 '-IN N r OCH,
11-29 k.. NQ "0 N 528.1 96%o F S
Embodiment 11: Preparation of Compound 11-66 0H OH OH + , NH2 HCI NH'Alloc H ,Alloc
0 11a 11b 11c 11d 11e 11f OBn O OH 0
Alloc 10a O 2a O N
11g 11h 11i 11-66 Preparation of Compound 1Ic: In 100 mL dichloromethane, Compound 11a (5.00 g, 58 mmol), Compound 1lb (5.98 g, 64 mmol), HATU (33.0 g, 87 mmol) and DIPEA (30 mL, 174 mmol) were stirred at room temperature overnight. TLC showed the reaction was complete, and the mixture was added with 100 mL water and extracted with dichloromethane (30 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 6.Og product.
Preparation of compound I1d: Compound 1Ic (1.00 g, 8.0 mmol) was dissolved in 240 mL dichloromethane, then added Grubbs II catalyst (260 mg, 0.32 mmol), and refluxed for 12 hours under nitrogen protection. TLC showed the reaction was complete, and the mixture was concentrated to give a crude product, which was separated by column chromatography to give 150 mg product.
Preparation of Compound 1le: Compound 11d (150 mg, 1.54 mmol) was dissolved in 4 mL anhydrous tetrahydrofuran, and replaced with nitrogen for three times. The mixture was cooled to -78 °C and 2.5M n-butyllithium solution (0.62 mL, 1.54mmol) was added slowly under N2 atmosphere. After addition, the mixture was stirred at this temperature for 2 hours. Then allyl chloroformate (186 mg, 1.54 mmol) was added by dropwise. After addition, the mixture was stirred for 2 hours, and TLC showed reaction complete. The reaction mixture was poured into saturated ammonium chloride solution and
then extracted with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated to give 235 mg oily product.
Preparation of Compound 1If: Compound 1le (235 mg, 1.3 mmol) was dissolved in 3 mL anhydrous tetrahydrofuran, and 1M diisobutylaluminum hydride solution (1.7 mL, 1.7 mmol) was added slowly at -78 °C under nitrogen protection. After addition, the mixture was stirred at this temperature for 2 hours. TLC showed reaction complete. The reaction mixture was poured into saturated potassium sodium tartrate solution, and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated to give 200mg oily product.
Preparation of Compound 1Ig: Compound 1If (200 mg, 1.1 mmol) was dissolved in 3 mL methanol, and p-toluenesulfonic acid monohydrate (21 mg, 0.11 mmol) was added, and the mixture was stirred at room temperature for 5 hours. TLC showed reaction complete. The mixture was added with saturated sodium bicarbonate solution till neutral, and extracted with dichloromethane (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated to give a crude product, which was separated by column chromatography to give 180 mg oily product.
Preparation of Compound 1Ih: Compound 1Ig (180 mg, 0.65 mmol) and Compound I0a (150 mg, 0.75 mmol) were dissolved in 15 mL acetonitrile. Under nitrogen protection and at -20 °C, IM solution of tin tetrachloride in dichloromethane (0.95 mL, 0.95mmol) was added dropwise. After addition, the mixture was stirred at this temperature for 3 hours. The mixture was added with saturated sodium bicarbonate solution, stirred for 30 min, and seperated. The aqueous phase was extracted with dichloromethane. The organic phases were combined, washed with brine, dried and concentrated to give 300 mg
solid. The solid was dissolved in 5 mL tetrahydrofuran, and tetrakis(triphenylphosphine)palladium (55 mg, 0.065 mmol) and morpholine (5 g, 55 mmol) were added and reacted at room temperature for 2 hours. TLC showed the reaction was complete. The mixture was concentrated, and the residue was separated by column chromatography to give 150mg product.
Preparation of Compound 1Ii: In 3 mL solution of T3P in ethyl acetate, Compound 11h (70 mg, 0.22 mmol) and Compound 2a (86 mg, 0.32 mmol) were reacted at 100 °C for 1.5 hours in a pressured reactor. The mixture was cooled, diluted with saturated NaHCO 3, and extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by column chromatography to give 100 mg crude product.
Preparation of Compound 11-66: In 3 mL DMA, Compound lii(100 mg, 0.18 mmol) and lithium chloride (37 mg, 0.88 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and 2N hydrochloric acid was added to adjust pH to 3-4. The mixture was filtered, and the solid was dried under vacuum to give 30mg product. 1 HNMR (400MHz, CDC 3) 6: 7.28 (d, 2H, J=8.0 Hz), 7.21(m, 1H), 7.05-7.15 (m, 5H), 6.98-7.01 (m, 1H), 6.91 (q, 1H, J=8.4 Hz), 6.85(m, 1H), 6.69(m, 1H), 6.63(m, 1H), 5.88 (d, 1H, J=7.6 Hz), 5.78(d, 1H, J=7.6 Hz), 5.69(m, 4H), 5.46 (m, 1H), 5.32(m, 1H), 5.28(s, 1H), 5.15(s, 1H), 5.03(m, 2H), 4.62(dd, 1H, J=3.6, 11.2 Hz), 4.49(dd, 1H, J=4.0, 10.8 Hz), 4.07(t, 2H, J=14.4 Hz), 3.44 (d, 1H, J=18.8 Hz), 3.27 (m, 1H), 2.57 (m, 2H), 2.30 (m, 2H); ESI-MS m/z (M+H)* 480.1.
With the same way, the following compounds were synthesized:
Compound Structure LCMS Purity ([M+H]+)
OH 0
11-34 ° 538.2 96% F S \1
OH 0
11-65 N494.1 94 F F
OH 0
O N II-67 512.2 93%
Embodiment 12: Preparation of Compound11-101
Boc OBn0 Y NBoc OBn O N'Boc OBn0 2a N l a NN olt: NN NH 2 HNO IN 0 NN H 0H 0 12a 12b 12c 12d
OBn O OH 0
0 0 O F \z x F\I /
F S F 12e 11-101
Preparation of Compound 12b: In 10mL tetrahydrofuran, Compound 12a (520 mg, 2.6 mmol), Compound 10a (570mg, 2.0 mmol) and DBU (490 mg, 3.3 mmol) were stirred at 55 °C overnight. The mixture was concentrated, added with 30 mL water and extracted with ethyl acetate (30 mL x 3), and the organic phases were combined, dried and concentrated to give a crude product, which was separated by column chromatography to give 720 mg product.
Preparation of Compound 12c: Compound 12b (720 mg, 1.6 mmol), ethyl glyoxalate (50% toluene solution, 1.66 g, 8.3 mmol) and acetic acid (20 mg,
0.3 mmol) were refluxed in 10 mL toluene for 6 hours. After the the reacton was complete, the mixture was diluted with 30 mL ethyl acetate, and washed with sodium bicarbonate solution and brine. The organic phases were dried and concentrated to give a crude product, which was separated by column chromatography to give 450 mg product.
Preparation of Compound 12d: Compound 12c (400 mg, 0.76 mmol) was dissolved in 15 mL dichloromethane and added with 5 mL trifluoroacetic acid, and the mixture was stirred at room temperature for 2 hours. The mixture was dried and added with 10 mL water, cooled in ice-water bath, added with saturated sodium bicarbonate solution to pH = 9-10, and stirred at room temperature overnight. The reaction solution was extracted with dichloromethane and the organic phases were dried and separated by silica gel plate to give 150 mg product.
Preparation of Compound 12e: In 6 mL solution of T3P in ethyl acetate, Compound 12d (150 mg, 0.39 mmol) and Compound 2a (156 mg, 059 mmol) were reacted at 100 °C for 1.5 hours in a pressured reactor. The mixture was cooled, diluted with water, and then extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and separated by silica gel plate to give 100mg product.
Preparation of Compound I-101: In 1 mL DMA, Compound 12e (100 mg, 0.16 mmol) and lithium chloride (35 mg, 0.83 mmol) were reacted at 100 °C for 3 hours. After the reaction finished, the mixture was diluted with 10 mL water, and added with 2N hydrochloric acid to adjust pH to 5-6. The mixture was filtered, and the solid was dried under vacuum to give 27mg product. 1 HNMR (400MHz, CDC 3) 6: 7.72 (d, 1H, J=6.0 Hz), 7.30 (m, 1H), 7.10-7.17(m, 2H), 6.85-7.02(m, 2H), 6.66-6.78(m, 1H), 6.38-6.51 (m,1H), 6.19 (d, 1H, J=6.0 Hz), 5.09(m, 1H), 4.74 (m, 1H), 4.55 (m, 1H), 4.42(m, 1H),3.84-4.00 (m, 2H),
3.73(m, 2H), 3.60 (m, 2H), 3.40 (m, 2H), 2.88 (m, 1H), 1.84 (m, 1H), 1.52 (m, 2H); ESI-MS m/z (M+H)* 537.2.
Embodiment 13: Preparation of Compound111-1 0 OH O 0O N)LN
F F\' \/ FF S F z
F 511-5 111-1
Preparation of Compound 111-1: In 1 mL N,N-dimethylacetamide, Compound II-5 (50 mg, 0.1 mmol), chloromethyl methyl carbonate (25 mg, 0.2 mmol), potassium carbonate (28 mg, 0.2 mmol) and potassium iodide (3 mg, 0.02 mmol) were reacted at 60 °C for 5 hours. TLC showed the reaction was complete, and the mixture was added with water to quench. IN hydrochloric acid was added to adjust pH to 3-4. The solid was filtered, dried, and separated by column chromatography to give 48 mg product. 1 HNMR (400MHz, DMSO-d6) 6: 7.37-7.44 (m, 2H), 7.13-7.18 (m, 2H), 7.10 (m, 1H), 6.93(m, 1H), 6.85 (t, 1H, J=7.6 Hz ), 5.75(m, 1H), 5.70(m, 1H), 5.66 (m, 2H), 5.43(d, 1H, J=14.8 Hz), 4.43(dd, 1H, J=2.4, 9.6 Hz), 4.10(dd, 1H, J=2.8, 10.8 Hz), 4.07(d, 1H, J=14.4 Hz), 3.75 (d, 1H, J=12.0 Hz), 3.72 (s, 3H), 3.44 (m, 1H), 3.02(d, 1H, J=11.2 Hz), 1.76(m, 1H), 1.13(m, 1H), 0.48(m, 1H), 0.24(m, 1H); ESI-MS m/z (M+H)* 598.1.
Embodiment 14: Preparation of Compound111-2 0
OHO 00 O N O O N' N O O 0 --- N' N O
11-6 111-2
Preparation of Compound 111-2: In 1 mL N,N-dimethylacetamide, Compound 11-6 (40 mg, 0.08 mmol), chloromethyl methyl carbonate (25 mg, 0.2 mmol), potassium carbonate (28 mg, 0.2 mmol) and potassium iodide (3 mg, 0.02 mmol) were reacted at 60 °C for 5 hours. TLC showed the reaction was complete, and the mixture was added with water to quench. IN hydrochloric acid was added to adjust pH to 3-4. The solid was filtered, dried, and separated by column chromatography to give 35mg product. 1 HNMR (400MHz, DMSO-d6) 6: 7.40-7.42 (m, 2H), 7.25 (d, 1H, J=7.6 Hz), 7.15 (m, 1H), 7.10(m, 1H), 7.00 (d, 1H, J=7.2 Hz), 6.84 (t, 1H, J=7.6 Hz ), 5.75(m, 4H), 5.43(d, 1H, J=16.4 Hz), 4.57(dd, 1H, J=3.2, 9.6 Hz), 3.96-4.03(m, 3H), 3.73 (s, 3H), 3.51 (t, 1H, J=10.0 Hz), 3.41 (s, 1H), 0.75(t, 2H, J=8.4 Hz), 0.50(m, 2H); ESI-MS m/z (M+H)* 598.1.
Embodiment 15: Preparation of Compound111-57 0
OHO0) 'N 0 0
F F s
1-77 Fill-57
Preparation of Compound 111-57: In 1 mL N,N-dimethylacetamide, Compound 1-77 (49 mg, 0.1 mmol), chloromethyl methyl carbonate (25 mg, 0.2 mmol), potassium carbonate (28 mg, 0.2 mmol) and potassium iodide (3 mg, 0.02 mmol) were reacted at 60 °C for 5 hours. TLC showed the reaction was complete, and the mixture was added with water to quench. IN hydrochloric acid was added to adjust pH to 3-4. The solid was filtered, dried, and separated by column chromatography to give 43mg product. 1 HNMR (400MHz, DMSO-d6) 6: 7.40 (m, 2H), 7.16(m, 3H), 6.91 (m, 2H), 5.83 (d, 1H, J=7.2 Hz), 5.74(m, 1H), 5.57(m, 1H), 5.44 (m, 1H), 5.29(s, 1H), 4.94(d, 1H, J=13.6Hz),4.21(d,1H,J=14.4Hz),3.74(s,3H),2.45(s,1H),2.05(m,4H), 1.93(m, 2H); ESI-MS m/z (M+H)* 582.1.
With the same way, the following compounds were synthesized: LCMS Compound Structure M+H]+) Purity
HaC'O 00 OoSO O
-3 614.2 93%
111-4OtON O OCH 1114 N N~4O616.2 97%
H CO 3 AO
N 111-5 N 580.2 95%
H3 s O
III-6 N.580.2 950
00 HC F YION
,-10 580.2 95%
0~~
H3 c,0
00
00
111-18 0 ,, 596.2 950
00
111-21 61 56.2 940
0 .
C 5 2O(H0
00
11HA5 Q' 612.2 06
0Nw
00
111-33 626.2 970
0
111-52 N 40640.2 97%o
0 C2 H 5 O--0 0
111-54 N, NAo 612.2 96%o
0
111-56 N.NNO640.2 95%
00
0 N--T N 111-59 NN 564.2 95%
111-61 YI-N) 564.2 96%o F~0X
00
111-66 ~ N 'N 596.2 950
0 1 (H 3 C) 2 HC0 A0-\
111-67 NN) 610.2 940
0 HO-P O O
IV-1 N) 604.2 93% IV-~ II
0 0 HCO O H3CO 00 O
IV-3 0 - 780.2 95% F F
0 HO-,
IV-9 NNo 620.5 93%
0 HO-pI
F F IV-110 O62.2 79N 96% H3 COA( o
IV-12 °1° 796.2 96% 0'
F HCO O0 0 -0 0
0V1 0 796.2 95%
Embodiment 16: In vitro bioactivity and cytotoxicity study Test compounds: the compounds of the present disclosure: Compound I-1, Compound 1-5, Compound 1-7, Compound 1-8, Compound 1-9, Compound 1-10, Compound 1-14, Compound 1-21, Compound 1-65, Compound 1-66, Compound 1-69, Compound 1-77, Compound 1-81, Compound 1-83, Compound 1-85, Compound 1-89, Compound 11-1, Compound 11-2, Compound 11-5, Compound 11-6, Compound 11-7, Compound11-8, Compound11-9,
Compound 11-10, Compound 11-13, Compound 11-14, Compound 11-17, Compound 11-18, Compound 11-22, Compound 11-29, Compound 11-34, Compound 11-65, Compound 11-66, Compound 11-67, Compound 11-101; control compounds: VX-787, Baloxavir acid.
Test method for In vitro bioactivity study: MDCK cells were seeded into 384-well cell cultrue plate at a density of 2,000 cells/well, and then incubated at 37 °C overnight in a 5% CO 2 incubator. On the following day, the compounds were diluted and added into the wells (3-fold dilutions, 8 test concentrations), and the influenza virus A/PR/8/34 (HINI) strain was then added to the cell culture wells at 2*TCID90 per well, and the final concentration of DMSO in the medium was 0.5%. The cell plate was incubated at 37 0 C for 5 days in the 5% CO 2 incubator. After 5 days of culture, the cell viability was measured using the cell viability detection kit CCK8. The raw data were subjected to nonlinear fitting analysis of the inhibition rate and cytotoxicity of the compounds using GraphPad Prism software to obtain EC5 0 values (see Table 1 for the results).
Method for cytotoxicity study: The cytotoxicity assay and antiviral activity assay of the compounds were performed in parallel, except for the absence of virus, other experimental conditions were consistent with the antiviral activity assay. After 5 days of culture, the cell viability was measured using the cell viability detection kit CCK8. Raw data were used for calculating compound cytotoxicity (CC 5 o) (see Table 1 for results).
Table 1: Cytotoxicity and inhibitory activity of compounds against influenza virus A/PR/8/34 (HINI) Results (nM) CPD ID EC50 CC5 o CPD ID EC50 CC5 o CPD ID EC50 CC5 o I-1 0.50 >1000 1-81 0.19 >1000 11-13 0.38 >1000 1-5 0.44 >1000 1-83 0.21 >1000 11-14 0.31 >1000 1-7 0.83 >1000 1-85 0.18 >1000 11-17 0.26 >1000
1-8 0.75 >1000 1-89 0.17 >1000 11-18 0.28 >1000 1-9 0.40 >1000 11-1 0.45 >1000 11-22 0.36 >1000 1-10 0.70 >1000 11-2 0.51 >1000 11-29 0.57 >1000 1-14 0.32 >1000 II-5 0.22 >1000 11-34 0.39 >1000 1-21 0.60 >1000 11-6 0.26 >1000 11-65 0.45 >1000 1-65 0.37 >1000 11-7 0.93 >1000 11-66 0.18 >1000 1-66 0.58 >1000 11-8 0.47 >1000 11-67 0.48 >1000 1-69 0.35 >1000 11-9 0.28 >1000 11-101 0.94 >1000 1-77 0.16 >1000 11-10 0.24 >1000 VX-787 1.4 >100 Baloxavir 1.4 >1000 acid The results indicate that when compared with the control compounds, the compounds of the present disclosure had superior activity against HINI and had low cytotoxicity.
Embodiment 17: Rat PK study Intravenous injection: about 2 mg of Compound11-5, Compound 11-6 and Compound 1-77 were accurately weighed out and added with appropriate amount of DMA, followed by vortex to a clean solution. An appropriate volume of 30% Solutol HS-15 aqueous solution and saline were added and vortexed, so that DMA: 30% Solutol HS-15: saline was 20: 20: 60 (v/v/v). The solution was filtered to give a 0.05 mg-mL-1 pharmaceutical preparation. SD rats were given a single injection of 0.25 mg-kg-1 of Compounds11-5, 11-6 and 1-77 intravenously. 0.20 mL of blood was collected from the jugular vein before administration and 0.083 h, 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h after administration, and placed in an EDTA-K 2 anticoagulation tube. 150 pL of whole blood was accurately pipeted immediately, and added into a test tube to which 450 pL of acetonitrile has been added to precipitate proteins, and the tube was vortexed, and placed on wet ice. It was stored in a -90 ~ -60 °C refrigerator for biological sample analysis. The concentration of the corresponding compound in the plasma of S-D rats was determined by LC-MS/MS analysis. The corresponding pharmacokinetic parameters were calculated using a non-compartmental model in Pharsight Phoenix 7.0. See
Table 2a for the results.
Intragastric administration: about 4mg of Compound 111-2 was accurately weighed out and added with appropriate amount of PEG400, followed by vortex to a clean solution. An appropriate volume of 30% Solutol HS-15 aqueous solution and saline were added, and follwed by vortex to give a pharmaceutical preparation of a concentration of 0.3 mg-mL-1, with PEG400: 30% Solutol HS-15: saline = 2: 2: 6 (v/v/v). SD rats were given a single oral administration of 3.0 mg-kg-1 of Compounds 111-2, and the concentration of Compound 11-6 in the plasma of S-D rats was determined before administration and 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h after administration. See Table 2b for the results.
Table 2a: PK Parameters (Intravenous Injection) of Test Compounds
PK (i.v.) Compound 11-5 11-6 1-77 Ti/2 2.49 2.97 2.96 (h)
(ngAhmoi 187 276 307 CL 20.9 13.6 13.0 (mL-kg- -min-'
3.69 3.12 2.77 (L kg)
Table 2b: PK Parameters (intragastric administration) of Test Compounds Compound PK (i.g.) Copo2 III-2 T1/2 3.32 (h) Tmax(h) 1.67 Cmax 253 (ng-mL-1) AUCo-t 1377 (ng-h-mL- 1 )
F (%) 47.2
The above results indicate that the compounds of the present disclosure have a low clearance rate and a long half life. The compounds of the present disclosure are effective for being prodrug and have a high absorption in vivo.
Embodiment 18: Efficacy on Mice Female BALB/c mice were inoculated with influenza A virus (HINI, A/WSN/33) by intranasal administration to establish an IAV mouse infection model. The vehicle, Compound 111-2 (15 mpk) or oseltamivir phosphate (15 mpk) were orally administered twice a day. Animal weight and survival status were monitored daily during the test, and on the 5th day, some animals were killed to take lung tissue for virus titer detection, and the remaining mice were used for survival rate monitoring. The in vivo anti-influenza virus efficacy of the test compound was determined by virus titer in lung tissue, mouse body weight change and survival rate.
Virus titer in lung tissue: On the 5th day after virus infection, the average virus titer in the lung tissue of mice in the vehicle control group reached 7.20 Log 10 (number of plaques per gram of lung tissue), the average virus titer in the lung tissue of mice in the oseltamivir phosphate group was 3.74 Log 10 (number of plaques per gram of lung tissue). Compared with the vehicle group, oseltamivir phosphate significantly inhibited the replication of the virus in mice, and the average virus titer decreased by 3.46 Log 10 (number of plaques per gram of lung tissue), and the difference was very statistically significant (p<0.01) between the results, showing the expected efficacy; the average virus titer in the lung tissue of mice on the 5th day after treatment with test compound 111-2 was 3.28 Log 10 (number of plaques per gram of lung tissue) ), and compared with the vehicle group, the test compound significantly inhibited the replication of the virus in mice, and the average virus titer decreased by 3.92 Log 10 (number of plaques per gram of lung
tissue), and the difference was extremely statistically significant (p < 0.001) between the results, which is superior to the control compound oseltamivir phosphate (Table 3).
Table 3: Virus Titer in Lung Tissue Influenza Virus Titer Statistical analysis Group Log10 (plaques (Compared with the solvent group) number/gram of lung) Mean difference Statistic difference Solvent 7.20+0.1024 NA NA Oseltamivir 3.74+0.5205 3.46 **(p<0.01) phosphate Compound 111-2 3.28+0.2813 3.92 ***(p<0.001)
**P<0.01 means very significant difference, ***P<0.001 means extremely significant difference
Body weight change and result analysis: The mice in the vehicle control group showed significant weight loss on the 3rd day after infection, and then continued to decline or even die; the weight of the mice in the oseltamivir phosphate group and the Compound 111-2 group remained stable during the experiment, had no significant decline, and the mice were in good health.
Survival rate and result analysis: the mice in the vehicle control group were found dead on the 7th day after infection, and on the 10th day, all mice died or were euthanized due to weight loss to the humanity end point, and the survival rate was 0%; the mice in the oseltamivir phosphate group and in the Compound 111-2 group maintained healthy during the experiment, and all animals survived to the predetermined experimental end point with a survival rate of 100%, indicating excellent anti-influenza efficacy in vivo.
The above description of the embodiments is merely to help understanding the method and the core concept of the present disclosure. It should be noted that, for those ordinary skilled in the art, various improvements and modifications can be made to the present disclosure without depart from the technical
principle of the present disclosure, and these improvements and modifications also fall within the protective scope of the present disclosure.
Claims (42)
1. A pyridone derivative represented by Formula (I) or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof,
W o o
A ,M'N R
(R7)m
wherein: (1) A is selected from N or CR1 , R1 is selected from hydrogen, cyano, hydroxy, halogen, carboxyl, ester, amide, sulfonyl amide; or, R1 is selected from the following unsubstituted or substituted groups: C1-6hydrocarbyl,C 1.6 hydrocarbyloxy,C 1 .6 hydrocarbylamino,C 1.6 hydrocarbylsulfydryl, carbonyl hydrazide,C 1.6 hydrocarbyl carbonyl,C 1.6 hydrocarbylamino carbonyl,C 16. hydrocarbylcarbonyl amino,C1. 6 hydrocarbyloxy carbonyl,C 1.6 hydrocarbylsulfinyl,C 1.6 hydrocarbylamino carbonylamino,C 3 .6 cycloalkyl, C 3 .6 cycloalkoxy,C 3 .6 cycloalkylamino,C 3 .6 cycloalkylsulfydryl,C 3 .6 cycloalkylcarbonyl,C 3 .6 cycloalkylamino carbonyl,C 3.6 cycloalkylcarbonyl amino, C 3 .6 cycloalkylamino carbonylamino,C 4 8. heterocycloalkyl, C 4 8.
heterocycloalkoxy, C 4 .8 heterocycloalkylamino, C 4 .8 heterocycloalkyl
sulfydryl, C 4 .8 heterocycloalkyl carbonyl, C 4 8. heterocycloalkylamino
carbonyl, C 5 . 1 0 aryl, C 5 . 1 0 aryloxy, C5 . 10 aryloxy hydrocarbyl, C 5 . 10 arylamino,
C 5 . 1 0 aryl sulfydryl, C 5 .1 0 aryl carbonyl, C 1 .6 hydrocarbyl sulfonyl, C1 .6
hydrocarbyl sulfonylamino, C 3 .6 cycloalkyl sulfonyl, C 3 .6 cycloalkyl sulfonylamino,C5-10 aryl sulfonyl,C5.1o aryl sulfonylamino, aminooxalyl amino, aminooxalyl,C 5 .10 arylamino carbonyl orC5 1. 0 arylamino carbonylamino; (2) M is selected from N or CR 2 , R2 is selected from hydrogen, cyano, hydroxy, halogen, carboxyl, ester, amide, sulfonyl amide; or, R2 is selected from the following unsubstituted or substituted groups: C 16 hydrocarbyl,C 1.6 hydrocarbyloxy,C 1 .6 hydrocarbylamino,C 1.6 hydrocarbylsulfydryl, carbonyl hydrazide,C 1.6 hydrocarbyl carbonyl,C 1.6 hydrocarbylamino carbonyl,C 1.6 hydrocarbylcarbonyl amino,C1. 6 hydrocarbyloxy carbonyl,C 1.6 hydrocarbylsulfinyl,C 1.6 hydrocarbylamino carbonylamino,C 3 .6 cycloalkyl, C 3 .6 cycloalkoxy,C 3 .6 cycloalkylamino,C 3 .6 cycloalkylsulfydryl,C 3 .6 cycloalkylcarbonyl,C 3 .6 cycloalkylamino carbonyl,C 3.6 cycloalkylcarbonyl amino, C 3 .6 cycloalkylamino carbonylamino,C 4 .8 heterocycloalkyl,C 48. heterocycloalkoxy,C 4 .8 heterocycloalkylamino,C 4 .8 heterocycloalkyl sulfydryl,C 4 .8 heterocycloalkyl carbonyl,C 48. heterocycloalkylamino carbonyl,C 5.10 aryl,C 5 .1 0 aryloxy,C 5 .1 0 aryloxy hydrocarbyl,C 51. 0 arylamino, C 5 . 10 aryl sulfydryl,C 5 .10 aryl carbonyl,C 1 .6 hydrocarbyl sulfonyl,C1 .6 hydrocarbyl sulfonylamino,C 3.6 cycloalkyl sulfonyl,C 3.6 cycloalkyl sulfonylamino, C5-10 aryl sulfonyl, C5-10aryl sulfonylamino, aminooxalyl amino, aminooxalyl,C 5.10 arylamino carbonyl orC 51. 0 arylamino carbonylamino; or, R 1 and R 2 are connected and form a first ring together with carbon atoms connected therewith, or R 2 and R 7 are connected and form a second ring together with carbon atoms connected therewith; (3) Q is selected from N or CR 3 , R 3 is selected from hydrogen, cyano, carboxyl, ester, amide; or, R 3 is selected from the following unsubstituted or substituted groups: C1 .6 hydrocarbyl,C 3 .6 cycloalkyl,C 48. heterocycloalkyl, C 5 .1 0 aryl,C 3 .6 cycloalkyl sulfydryl, spirocyclic ring, bridged cyclic ring,C 3 .6 cycloalkyl sulfydrylC 1 .6 hydrocarbyl,C 3.6 cycloalkylC 1 .6 hydrocarbyl sulfydrylC 1.6 hydrocarbyl,C 3.6 cycloalkylC 1 .6 hydrocarbyl sulfydryl cycloalkyl,C 3 .6 cycloalkyloxy cycloalkyl, cycloamideCI 6 hydrocarbyl, cycloamide cycloalkyl, cyclosulfonylC 1.6 hydrocarbyl, cyclosulfonyl cycloalkyl; or, R 3 and R 4 are connected and form a third ring together with carbon atoms connected therewith; (4) R is selected from NH, carbonyl or CR 4R5 , R 4 and R5 are independently selected from hydrogen, cyano, carboxyl, ester, amide; or, R4 and R 5 are independently selected from the following unsubstituted or substituted groups: C1 .6 hydrocarbyl,C 1.6 hydrocarbyloxy,C 1.6 hydrocarbylamino,CI 6 hydrocarbylsulfydryl,C 1 .6 hydrocarbylcarbonyl,C1. 6 hydrocarbylamino carbonyl,C 1.6 hydrocarbylcarbonyl amino,C1. 6 hydrocarbyloxy carbonyl,C 1 .6 hydrocarbylamino amide,C 3 .6 cycloalkyl,C 3.6 cycloalkoxy,C 3.6 cycloalkylamino,C 3.6 cycloalkylsulfydryl,C 36. cycloalkylcarbonyl,C 3 .6 cycloalkylamino carbonyl,C 3.6 cycloalkylamino carbonylamino,C 3 .6 cycloalkylcarbonyl amino,C 4 .8 heterocycloalkyl,C 48. heterocycloalkoxy,C 4 .8 heterocycloalkylamino,C 4 .8 heterocycloalkyl sulfydryl,C 4 .8 heterocycloalkyl carbonyl,C 48. heterocycloalkylamino carbonyl,C 5.10 aryl,C 5 .10 aryloxy,C 5 .1 0 aryloxyC1 .6 hydrocarbyl,C 5 .10 arylamino,C 5 .1 0 aryl sulfydryl,C 5 .10 aryl carbonyl,C 5 .10 arylamino carbonyl or C 5 . 1 0 arylamino carbonylamino; or, R 4 and R 5 are connected and form a fourth ring together with carbon atoms connected therewith; (5) R 6 is selected from hydrogen or the following unsubstituted or substituted groups: C1 .6 hydrocarbyl,C 1.6 hydrocarbyloxy,C 1.6 hydrocarbylamino,C 1 -6hydrocarbylsulfydryl, carbonyl hydrazide, C 1-6 hydrocarbyl carbonyl,C 1-6hydrocarbylamino carbonyl, C 1-6 hydrocarbylcarbonyl amino,C 1-6hydrocarbyloxy carbonyl,C1.-6 hydrocarbylsulfinyl,C 1.6 hydrocarbylamino carbonylamino,C 3 .6 cycloalkyl, C 3 .6 cycloalkoxy,C 3 .6 cycloalkylamino,C 3-6 cycloalkylsulfydryl,C 3-6 cycloalkylcarbonyl,C 3-6 cycloalkylamino carbonyl,C 3-6 cycloalkylcarbonyl amino, C 3 .6 cycloalkylamino carbonylamino,C 4 .8 heterocycloalkyl,C 48.
heterocycloalkoxy,C 4 .8 heterocycloalkylamino,C 4 8. heterocycloalkyl sulfydryl,C 4 .8 heterocycloalkyl carbonyl,C 48. heterocycloalkylamino carbonyl,C 5.10 aryl,C 5 .10 aryloxy,C 5 .10 aryloxy hydrocarbyl,C 51. 0 arylamino, C 5 . 1 0 aryl sulfydryl,C 5 .10 aryl carbonyl,C 1 .6 hydrocarbyl sulfonyl,C 1 .6 hydrocarbyl sulfonylamino,C 3.6 cycloalkyl sulfonyl,C 3.6 cycloalkyl sulfonylamino,C 5-10 aryl sulfonyl,C 5.1 0 aryl sulfonylamino, aminooxalyl amino, aminooxalyl,C 5 .10 arylamino carbonyl orC5 .10 arylamino carbonylamino; or, R 6 is a fifth ring; or, R 6 and R are connected and form a sixth ring together with a nitrogen atom both connected therewith, and the sixth ring is monocyclic, spiro, fused cyclic, bridged cyclic or polycyclic, and optionally contains 1, 2, 3 or more groups independently selected from heteroatom, C=O, S=O or -SO 2 , in addition to the nitrogen atom which R and R6 are both connected with;
(6) m is 0, 1, 2, 3, 4 or 5, and R 7 is selected from hydrogen, hydroxy, cyano, halogen, carboxyl, ester, sulfonyl amide, amide; or, R7 is selected from the following unsubstituted or substituted groups: C 1 6. hydrocarbyl,C1 .6 hydrocarbyloxy,C 1 .6 hydrocarbylamino,C 1.6 hydrocarbylsulfydryl, carbonyl hydrazide,C 1.6 hydrocarbyl carbonyl,C 1.6 hydrocarbylamino carbonyl,C 16. hydrocarbylcarbonyl amino,C1. 6 hydrocarbyloxy carbonyl,C 1.6 hydrocarbylsulfinyl,C 1.6 hydrocarbylamino carbonylamino,C 3 .6 cycloalkyl, C 3 .6 cycloalkoxy,C 3 .6 cycloalkylamino,C 3 .6 cycloalkylsulfydryl,C 3 .6 cycloalkylcarbonyl,C 3 .6 cycloalkylamino carbonyl,C 3.6 cycloalkylcarbonyl amino, C 3 .6 cycloalkylamino carbonylamino,C 4 8. heterocycloalkyl,C 48. heterocycloalkoxy,C 4 .8 heterocycloalkylamino,C 4 .8 heterocycloalkyl sulfydryl,C 4-8 heterocycloalkyl carbonyl,C 48. heterocycloalkylamino carbonyl,C 5.10 aryl,C 5 .1 0 aryloxy,C 5 .1 0 aryloxy hydrocarbyl,C 51. 0 arylamino, C 5 .1 0 aryl sulfydryl,C 5 .1 0 aryl carbonyl,C 1 .6 hydrocarbyl sulfonyl,C 1 .6 hydrocarbyl sulfonyl amide,C 3.6 cycloalkyl sulfonyl,C 36. cycloalkyl sulfonyl amide, C 5 . 10 aryl sulfonyl,C 5 .10 aryl sulfonyl amide, aminooxalyl amino, aminooxalyl,C 5 .1 0 arylamino carbonyl orC 5 .1 0 arylamino carbonylamino; or, m is 2, 3, 4 or 5, and one or more pairs of neighboring R 7 are connected and form a seventh ring together with carbon atoms connected therewith; or, R 2 and R 7 are connected and form the second ring together with carbon atoms connected therewith; (7) X is selected from Y(CH 2 )., -CH(OCH 3), -CH(SCH 3), N, 0 or S, Y is a single bond, NH, 0 or S, and n is 0, 1, 2 or 3; (8) W is hydrogen or a group that is metabolized to a parent drug by chemical means and/or by the action of an enzyme in vivo; (9) Arl and Ar2 are independently selected from a phenyl ring, or a heteroaromatic ring containing 1, 2, 3 or more heteroatoms; (10) the first ring, the second ring, the third ring, the fourth ring, the fifth ring, and the seventh ring are independently an unsubstituted or substituted carbocyclic ring uninterrupted or interrupted by 1, 2, 3 or more selected from heteroatom, C=, S=O orSO 2 , and the first ring, the second ring, the third ring, the fourth ring, the fifth ring, and the seventh ring are independently monocyclic, spiro, fused cyclic, bridged cyclic or polycyclic.
2. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1, wherein Arl and Ar2 are both a phenyl ring and the pyridone derivative is represented by Formula (II): W O0 O o Ra A MN R
I~ (R7)m
(II) or, at least one of Arl and Ar2 is a heteroaromatic ring.
3. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1, wherein, in the heterocyclic ring or the heteroaromatic ring, a heteroatom is dependently selected from N, 0, or S.
4. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1, whrein A is CR 1 , M is CR2, and R 1 and R2 are connected and form the first ring together with carbon atoms connected therewith; and/or, Q is CR 3, R is CR4R5 , and R3 and R4 are connected and form the second ring together with carbon atoms connected therewith; and/or, R is CR 4R, and R4 and R 6 are connected and form the sixth ring together with carbon and nitrogen atoms connected therewith.
5. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1, wherein W is selected from the following groups: (a) -C(=O)-R; (b) -C(=O)-(CH 2)k-R, k is selected from 0-3; (c) -C(=O)-O-(CH 2)k-R, k is selected from 0-3; (d) -CH 2-0-R8 ; (e) -CH 2-0-C(=O)-R; (f) -CH 2-0-C(=O)-O-R 8; (g) -CH(-CH 3)-O-C(=O)-R 8 ; (h) -CH(-CH 3)-O-C(C=)-O-(CH 2)k-R, k is selected from 0-3; (i) -CH 2-0-P(=O)(OH) 2 ; (j) -CH 2-0-P(=O)(OPh)(NHR 8); (k) -CH 2-0-P(=)(OCH 20C(=0)OR) 2; R 8is selected from the following unsubstituted or substituted groups: C1 -6 hydrocarbyl, C1 .6 hydrocarbyloxy,
C 1 .6 hydrocarbylamino, C 1 .6 hydrocarbylsulfydryl, carbonyl hydrazide, C1 .6 hydrocarbyl carbonyl, CI6 hydrocarbylamino carbonyl, C1 .6
hydrocarbylcarbonyl amino, CI6 hydrocarbyloxy carbonyl, CI 6
hydrocarbylsulfinyl, CI6 hydrocarbylamino carbonylamino, C 3 .6 cycloalkyl,
C 3 .6 cycloalkoxy,C 3 .6 cycloalkylamino, C 3 .6 cycloalkylsulfydryl, C 3 .6 cycloalkylcarbonyl, C 3 .6 cycloalkylamino carbonyl, C 3 .6 cycloalkylcarbonyl
amino, C 3 .6 cycloalkylamino carbonylamino, C 4 .8 heterocycloalkyl, C 4 8.
heterocycloalkoxy, C 4 .8 heterocycloalkylamino, C 4 .8 heterocycloalkyl
sulfydryl, C 4 .8 heterocycloalkyl carbonyl, C 4 8. heterocycloalkylamino
carbonyl, C 5 .1 0 aryl, C 5 .1 0 aryloxy, C 5 .1 0 aryloxy hydrocarbyl, C 5 1. 0 arylamino,
C 5 . 10 aryl sulfydryl, C 5 . 10 aryl carbonyl, C 1 .6 hydrocarbyl sulfonyl, C1 .6 hydrocarbyl sulfonylamino, C 3 .6 cycloalkyl sulfonyl, C 3 .6 cycloalkyl sulfonylamino, C 5 . 1 0 aryl sulfonyl, C 5 .1 0 aryl sulfonylamino, aminooxalyl
amino, aminooxalyl, C 5 . 1 0 arylamino carbonyl or C 5 . 1 0 arylamino
carbonylamino.
6. The pyridone derivative or the stereoisomer, the pharmaceutically
acceptable salt, the solvate or the crystal thereof according to any one of claims 1
to 5, wherein when the sixth ring is a spiro ring, a common carbon atom of the
spiro ring and a nitrogen atom shared by the spiro ring and a parent ring are
adjacent or spaced by one atom.
7. The pyridone derivative or the stereoisomer, the pharmaceutically
acceptable salt, the solvate or the crystal thereof according to any one of claims 1
to 6, wherein when the sixth ring is a spiro ring, a ring in the spiro ring that shares
the nitrogen atom with a parent ring has an oxygen atom, a nitrogen atom or a
carbon atom at a position opposite to the nitrogen atom.
8. The pyridone derivative or the stereoisomer, the pharmaceutically
acceptable salt, the solvate or the crystal thereof according to any one of claims 1
to 7, wherein when the sixth ring is a spiro ring, a ring in the spiro ring that shares
the nitrogen atom with a parent ring is a 5-membered, 6-membered, 7-membered
or 8-membered ring, and another ring is a 3-membered, 4-membered, 5-membered or 6-membered carboatomic, oxygen-containing heterocyclic or sulfur-containing heterocyclic ring unsubstituted or substituted by a substituent selected from halogen,C 1.3 hydrocarbyl orC1 .3 halohydrocarbyl.
9. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 8, wherein when the another ring has a substituent, the substituent is selected from methyl, fluoro, chloro, bromo, monofluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, methoxymethyl, methoxyethyl, chloromethyl.
10. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 9, wherein in Formula (I), the sixth ring is selected from the following groups:
N N N O , N'
11. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 9, wherein the pyridone derivative is represented by Formula Ila or Formula Ilb: oo W-0 zW 0 0 z 00 0 N
N,"' G N ~ G N N
(R7 )m (Ry)m
11a , IIb
in Formula Ila and Formula Ilb, G is 0 or CH 2; Z is selected from CH 2 , 0 or S; p and q are respectively 0, 1 or 2, and the two are not 0 at the same time, and when Z is 0 or S, p+q is greater than or equal to 2; definitions of W, R 7 and m are respectively the same as the preceding claims.
12. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 11, wherein in Formula Ila and Formula Ilb, p+q = 1 or 2 or 3, and Z is C 2 ; or, p = 1 or 2, q= 1 or 2, and Z is 0 or S.
13. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 11, wherein R7 is selected from hydrogen, hydroxy, cyano, halogen, C 1 .6 hydrocarbyl, C 1 6. halohydrocarbyl, C 3 .6 cycloalkyl, C 1 .6 alkoxy C 1 .6 hydrocarbyl, hydroxy C 1 .6 hydrocarbyl, C 1 .6 hydrocarbyloxy.
14. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 13, wherein R7
is connected to a phenyl ring , R7 is selected from F, Cl, Br or methyl, and m is 1,
2 or 3.
15. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 11, wherein W is selected from the following groups: (a) -C(=O)-R; (b) -C(=O)-(CH 2)k-R, k is selected from 0-3; (c) -C(=O)-O-(CH 2)k-R, k is selected from 0-3; (e) -CH 2-0-C(=O)-R 8 ; (f) -CH 2-0-C(=O)-O-R; (g) -CH(-CH 3)-O-C(=O)-R 8 ; (h) -CH(-CH 3)-O-C(C=)-O-(CH 2)k-R, k is selected from 0-3; (i) -CH 2-0-P(=O)(OH) 2 ; (j) -CH 2-0-P(=O)(OPh)(NHR 8); (k)
-CH 2-0-P(=)(OCH 20C(=0)OR) 2; R 8is selected from methyl, ethyl, isopropyl, or butyl.
16. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 5, wherein the pyridone derivative is represented by Formula Ic: W 0 0 0 c
E d NN)
(R7 )m
IIc
in Formula Ic, a, b, c and d are respectively 0, 1, 2 or 3, and a and b are not 0 or 3 at the same time, and c and d are not 0 or 3 at the same time; E is CH2 or 0;
K is CH2 or 0.
17. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 16, wherein in Formula I1c, a+b = 1 or 2 or 3, and c+d = 1 or 2 or 3.
18. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 16,wherein in Formula Ic, R 7 is selected from hydrogen, hydroxy, cyano, halogen,C 1 .6 hydrocarbyl,C 1.6 halohydrocarbyl,C 1.6 alkoxyC1 .6 hydrocarbyl, hydroxyC1 6 hydrocarbyl,C 1.6 hydrocarbyloxy, and R 7 disconnected to a phenyl ring.
19. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 5, wherein when the fifth ring is a bridged ring, the bridged ring is bicyclic or tricyclic, and a bridgehead carbon atom or a non-bridgehead carbon atom of the bridged ring is connected to a corresponding nitrogen atom on a parent ring.
20. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1 or 19, wherein when the fifth ring is a bridged ring, the bridged ring is selected from bicyclo[1.1.1]pentane, bicyclo[2.1.0]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.0]hexane, bicyclo[3.1.1]heptane, bicyclo[3.2.0]heptane, bicyclo[2.2.1]heptane, bicyclo[3.2.1]octane, bicyclo[3.3.0] octane.
21. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1 or 19 or 20, wherein when the fifth ring is a bridged ring, the bridged ring is unsubstituted or substituted by 1, 2, 3 or more substituents selected from fluoro, chloro, bromo, trifluoromethyl, -CH 2OH or -CH 20CH 3 .
22. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 5, wherein the pyridone derivative is represented by Formula Ild or Formula Ile:
0 W\ 0 R2 W0 0R1
N 0 N
IN
_(IRy)m (IRy)m S
lid Ile
in Formula Ild and Formula Ile, R 12 is selected from hydrogen, hydroxy, cyano, halogen,C 1.6 hydrocarbyl,
C 1 .6 halohydrocarbyl, C 1.6 alkoxyC 1 .6 hydrocarbyl, hydroxyC 1 .6 hydrocarbyl, C 1 .6 hydrocarbyloxy, carboxyl, amide or ester.
23. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 22, wherein R 1 2 is selected from hydrogen, fluoro, chloro, methyl, ethyl, isopropyl,
trifluoromethyl, methoxymethyl or hydroxymethyl.
24. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 22, wherein in Formula Ild or Ile, R 7 is selected from hydrogen, hydroxy, cyano, halogen,C 1 .6 hydrocarbyl,C 1.6 halohydrocarbyl,C1 6. alkoxyC1 6. hydrocarbyl, hydroxyC1 6. hydrocarbyl,C 1.6 hydrocarbyloxy, and R 7 is connected to a phenyl ring.
25. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 5, wherein R6 is selected from the following groups:
CH 2 OK 1
26. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 5, wherein when the sixth ring is a 4-membered, 5-membered, 6-membered or 7-membered monocyclic ring, Formula (I) further meets at least one of the following conditions: i) in addition to the nitrogen atom to which both R and R6 are connected, the sixth ring optionally contains one or two of oxygen atom, another nitrogen atom, C=O, S=0, SO 2 ;
ii) the sixth ring has at least one substituent selected from hydroxy, cyano, carboxyl, ester, sulfonyl amide, amide,C 2-6 alkenyl,C 3 .6 cycloalkyl,C 3 .6 halocycloalkyl,C 3.6 cycloalkoxy,C 1.6 hydrocarbyloxyC 1 .6 hydrocarbyl,C 1.6 hydrocarbyloxyC1. 6 hydrocarbyloxy,C 1.6 hydrocarbylamino,C 1.6 hydrocarbylsulfydryl, carbonyl hydrazide,C 1 .6 hydrocarbyl carbonyl,C 1.6 hydrocarbylamino carbonyl,C 1.6 hydrocarbylcarbonyl amino orC1.6 hydrocarbyloxy carbonyl; iii) the sixth ring has an intra carbon-carbon ethylenic bond, or the sixth ring has an exocyclic carbon-carbon ethylenic bond sharing one carbon atom with the sixth ring; iv) at least one of Arl and Ar2 is a nitrogen-containing heteroaromatic ring; v) at least one of A and M is N.
27. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 26, wherein, in the condition ii), the substituent in the sixth ring is selected from OCH2CH20CH 3
, -CH 20CHF 2, -CH 20CF 3, -CH 2 OH, -OH, -COOH, -COOCH3, -CONH 2, -OCH 2F, 0
-OCHF 2, -OCF 3 , -CH 20CH3, tCH2 +-
+
28. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1 or 26 or 27, wherein when the sixth ring is a 4-membered, 5-membered, 6-membered or 7-membered monocyclic ring, the sixth ring contains a total of 2 heteroatoms and the 2 heteroatoms are in para or meta positions, and one of the heteroatoms is a nitrogen atom connected to both R and R6 , and the other heteroatom is oxygen or nitrogen.
29. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 28, wherein the two heteroatoms contained in the sixth ring are all nitrogen atoms and the two nitrogen atoms are in opposite positions, while the sixth ring further has a C=O.
30. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1 or 26 or 27, wherein when the sixth ring is a 4-membered, 5-membered, 6-membered or
7-membered monocyclic ring, the sixth ring contains a total of1 heteroatoms which is the nitrogen atom connected to both R and R6,while the sixth ring has an intra carbon-carbon ethylenic bond or an exocyclic carbon-carbon ethylenic bond.
31. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1 or 26, wherein, in Formula (I), the sixth ring is selected from the following groups:
4' /~ o'4 O N/ N/NN N
0 M Q1N<,OH )22 2\ 3 VON ' 'OCF 3
VN VN -I
N N OCH 3 ; O(CH2) 2 O-< F'
32. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 5, wherein, in Formula (I), the sixth ring is an unsubstituted morpholine ring, and further meets at least one of the following conditions: i) one of A and M is N, and the other is correspondingly CR1 or CR 2 ,
while Q is CH; ii) at least one of Arl and Ar2 is a nitrogen-containing heteroaromatic ring containing 1 or 2 nitrogen atoms.
33. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 5, wherein when the sixth ring is a fused ring, the fused ring is a bicyclic ring, wherein one ring sharing a nitrogen atom with a parent ring is a saturated 5-membered or 6-membered ring and optionally contains one or two proups selected from 0, another N, C=O, S=0, SO 2 , and the other ring is a 3-membered, 4-membered, 5-membered or 6-membered saturated or unsaturated ring and optionally contains one or two groups selected from 0, N, C=O, S=0, SO 2
. 34. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1 or 33, wherein when the sixth ring is a fused ring, one ring of the fused ring sharing a nitrogen atom with a parent ring is a piperidine or piperazine ring, and the other ring is a 5-membered or 6-membered heteroaromatic ring or a saturated heterocyclic ring, which is unsubstituted or substituted by 1, 2, 3 or more substituents selected from hydroxy, cyano, carboxyl, ester, sulfonyl amide, amide, C 1 .6 alkyl,C 2-6 alkenyl,C1 .6 halohydrocarbyl,C1.3alkoxy,C 3.6 cyclohydrocarbyloxy,C 1 .6 hydrocarbyloxyC 1 .6 hydrocarbyl, C1-6 hydrocarbylamino,C 1 .6 hydrocarbylsulfydryl, carbonyl hydrazide,C1 .6 hydrocarbyl carbonyl,C 1 .6 hydrocarbyl sulfonyl amide,C1 6 hydrocarbylamino carbonyl,C 1 .6 hydrocarbylcarbonyl amino orC1 .6 hydrocarbyloxy carbonyl.
35. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1 or 33 or 34, wherein, in Formula (I), the sixth ring is selected from the following groups:
N O N O OOH 0 0; N \,, N--Q ; o 0*
H H 'NN NN 'C N OCH 3 NHSO 2 CH 3 N N N N N
CF 3
N N NO IN CH 3
36. The pyridone derivative or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to claim 1, wherein the pyridone derivative is selected from the following compounds:
N '4y6 N/ 0 0 Ny iN N
03 N (CH 2)20H 3 00F3 OH 0 0 OH O OH 0 OH OH
S NN N N
F F F F
1-5 1-6 1-7 1-8
0
o.0 j oo
C 0 X 0/
L±0 s rjo. F F 0 ; j1
0S 0/
NH 0 0 a
0 02 0.''n
_0 H
0 N 0 4 0 N N
N N .N NN N.N 'N N
1-29 1-30 1-31 1-32
OH 0OH0OH 0OH 0 0HN OHO -^ OHON) YAN^
,O N 0I~ Ny,," O- MroN NN, I.N N,~ y N'N N' ~HO>H3
'Jq I FI F" F s FF
OH00 OHO0SN OH 0O
0:"r- N 0 o O-N- OH N NN N N N N ~ ~ )N N NN
~~(-0 S S s s 1-37 1-38 1-39 1-40
OHO0 OHO0 OHO0 OHO0 --- N- _ - 0 \ SCF
NNN 'N
S S s s
1-41 1-42 1-43 1-44
OHO0 OHO0 OHO0 OHO0 1 1.11< 0 1 1.1 0 1 N1-K0.1\S F
F sF sF sF 1-45 1-46 1-47 1-48
OHO0 OHO0 OHO0OH OHO0 H 0N ~ N N-C/ 0 .~- 0 0~ N.)N N.. N r F
1-49 15 -115
OHO0 OH 0 HOHO0 H_ OHO0 H 0 _0 -N- 0 Nf>. N 0"N..) 0 N0~. 0 N N N 'N N.)
F -F - /F -F -/
F F F F 1-53 1-54 1-55 1-56
OHO0 0 OHO0 0 OH 0 OHO0
N N N N H, NH N
51-57 1-58 1-59 1-60
OHO0e- OHO0 OHO0 OHO0
NN N.N
sF F F 0F S F 1-61 1-62 1-63 F 1-64
OH m.OH 0 OHO OH 0F O, , N 0N NN. l NN 7 N N1 7 F- F-:s qSl qso 1-5F 1-66 1-67 F 1-68
OH 0 [7OH 0 F OH 0 £71 CF H0O 0 N10. y kr 0 N N<
NN iI1cN1IJ N Nz N-
N 020 020 CCV 1-69 1-70 1-71 1-72
F ,CF 3 OH 0 J~OCH3 OH 0 OH 0 0H 0 NZ< N N N. N 0- N .N N.N ) .N) NN
Qso NNZ
0c~o OQO 02 1-73 1-74 1-75 1-76
F CF, OH OH0OH 077 OH 0 0l JN N ) N 1:N, N
N N N
F- Cs F- s F _SFS F 1-77 F 1-78 F 1-79 18
OHO0l OH 0 F OH 07 OH N
~N )N NN N
FCS F F 1-81 F 1-82 1-83 1-84
0 C, OH 0 1 /OH OH0NQOH 0<F 0OH
OHN N N N N N N N F TNF F
' 1-85 1-86 1-87 1-88
OH 0O FF7(O 0 O OH 0 OH 0H F O 0I No~ N
N NI Nl N N
1-89 1-90 1-91 1-92
F ,CF 3
0 IA 3 OH 0 IIOH 0 OHI 0N N OH N l T N ><' Nz N N- N NN
) N .)N ~ ) N N N
F- CS F- C F- : F FS
F 1-93 F 1-94 F 1-95 1-96
H0O OHO0 OCH, OH 0 N 0"t N N N N N Nh N N, NLI110zz N N'N wo N 0 N 'L"'~
11-1 11-2 11-3 11-4
OHO0 0O 0OH OHO0 OHO0 NNj ""N NH NC O N N , N N NN NINo ' N' NLN)o N 0 N '
F F- F
sF sF F sF 511-5 11-6 11-7 11-8
0 OHNf 0 OHO0 OCH 3 OH0 N N'z N N ~ N0 NNN N' NN.NAoN NNk'o
sF sF F sF 11-9 11-10 11-11 11-12
OHO0 0 OHO0 OCH, OHO 0 OHO0
V 0 N1N 0 N N'Th N N-A N
XF.. F. F...
11-13 11-14 11-15 11-16
OHO0 OHO0 OCH, OHO0 OHO0 o N, 0 0
N -. .- A~oNN...,O N__
1117 11-18 11-19 11-20
OHO0 OH 0 OCH, OH 0 OHO0 NW .- 0 N~A 00. N NN~N-~J%~ "I N-< 0
- s /k.-/o
11-21 11-22 11-23 11-24
OH 0 OH OHO0O0OH OH OH 0 OCHF 2
F F F F 12 11-25 11-26 11-271-2
OHO0 OHO0 OHO0 o OHO0 0 N' 'N -- OCH 3 0,tTN--N -OH O N- N OH -- N y
N N'NI'o N N..oN .- N-NA'o NN-~..
FF -F s F F F 11-F 5 11-29 11-30 11-311-3
OHO0 OHO0 OHO0 0 O Oy' OH 0 LNzzNtNA O N'kN v N N N N"
F F~
F F F ; so F FS .. F 11-33 11-34 11-35 11-36
OHO0 OHO0 0 O OHO0 0YZ 0 0j'
' N N N N 'I
N NsNA.s
11-37 11-38 11-39 11-40
OHO0 OHO0O 0O
0
s s
11-41 11-42 11-43 11-44
OHO0 OHO0O 0O
N'' 0 NNN N N NN 0~ ~
F c F FS F
11-45 11-46 11-47 11-48
OHO0 OHO0 OHO0 OHO0
1N N 1 N N H01 N N C30 NS2H N N N N N
F- / F -\ F F
F F F F
11-49 11-50 11-51 11-52
OHO0 OHO H OHO0 H OHO 7 N NNNNQN N N N N 01N s N, ~ . N N Nt _N / NN N N N.O CF 3 ' .
511-53 11-54 11-55 11-56
OHO N OHO0 H OHO0 H N ON OHO0 N 7 NN N N N N N
N . ~ NN. NN NN N~N~ CF3
F - F- F
F F sF sF 11-57 11-58 11-59 11-60
OHO0 OHO0 OHO0 OHO0
'N ~"~01N 'N~a> N 'N~ N 0N
/F -F \ F ..
sF sF sF F
11-61 11-62 11-63 11-64
OHO0 OHO0 OHO0 OHO0
0 N,N 0N N
F F F F
11-65 11-66 11-67 11-68
OHO0 OHO0 OH0 OH 0
NF NN, N1N N"N0 N'0
F F0 0
11-69 11-70 11-71 11-72
OHO0 OHO0 OHO0 OHO0
N N~~~~N4 10 N'NNN.A~ON N .0
N N
F F CF,
11-73 11-74 11-75 11-76
OHO0 OHO0 OHO0 OHO0
N -N 0
Ng' N N j INN NN I N- N
11-77 11-78 11-79110
OH 0OHO0 OHO0 OHO0
NN N N~ NN..NNN OH
FF F~ F sF F F 11-81 11-82 11-83 11-84
OHO0 OCH, OHO0 OH 0 OH 0
N N N N OCH, F' N N * N N N' . N ' NrF
F - / F x FF F F sF F 11-85 11-86 11-87 11-88
O0OH0OH 0 OHO0
N N 0N IN0N
F F sF F sF IF F F
11-89 11-90 11-91 11-92
OHO0 OHO0 OHO0 OHO0
cI Br N'.N..o H3 C NNNADO F N
F- F ; S F- Cs F J( s F F F F 11-93 11-94 11-95 11-96 OHO0 OHO0 OHO0 OHO0 0 0 'kJ0 0 )N hzzt N N ~ z N, N, ktN, N
NNH N H N -N-'- N'4N' N N
F S H 2 N F -(Cs F F FF F OCH 3 F SCH 3 11-97 11-98 11-99 11-100
0OHO0 OHO0 OHO0O rOH 0 NN N N> 0 0 N., N N, N..NANCH 3 N,. QNHNN N 0 N
FF - F/F -/ F F F sF 11-101 11-102 11-103 1-0
OHO0 OHO0 0OHO 0 0 OHO 0 0 oy rN- Ny -0 N- N N, N OCH 3 N HN -. ) o N : , A'
FF -q F PD N
F sF 11-105 11-106 11-107 11-108
OHO0 OHO0 OHO0 OHO0
0l NN,>0 A N 0N 0 4 N-aC NN OH.t N .NN . C 2CH 2OCH 3 - H -F OCH 3
F- F- F. F.
sF S F sF F 11-109 11-110 11-111 11-112
H3 C HC O3 H3 C 0 H0 3 AO\ 0 0 0- \0 0 OA0\00 IA0-\ 0 OCH 3
NO 0 NNN5 01N( N6 1
F - F - F 11 F Z,
F sF sF F 111-1 111-2 111-3 111-4
H3 4 \ H3 C 0 HC0HC0 IA0-\ IO l- 0 0 IO ,\0 0 IA0\ 0OCH3
N N ON N 00 NN,O NNN~ N N0K~ N ~A~
F sF sF sF 111-5 111-6 111-7 111-8
H3 HC H3 C 0( H 3C 0 oO 0 o O 0- 0 0 IA0\0 0 IA0-\ 0 OCH 3 o- 00 N N'k'- 0 N"'o '
N- x~f 0 NF F F
111-9 111-10 111-11 111-12
0 H3C 03 0 HC0 HC
0O 0,\ A \ 0 0 IA0\0 0 IA0\ 0 OCH 3
1 N' ON N j--N-- 0 NN
NNNA0 NN.o< N"I N)NAI0 NNA0
cx
5111-13 111-14 111-15 111-16 o, , ,100H, H 3 C ,00 AO\ oAo\ 03 , 4 0 C, 4 A0\ OCH,
0~\N 0 0\H3 N 4 00 00 00 0
F NwJ F F NNA0 F N'NL~0
H, 0, 0 CH 0NC 0 0,C 0
N N $0 N Ny 0 N0- 0, N Nl ~ CIN N"W ciN N ~0 cl ,,N , LOClIN N'N.A
111-21 111-22 111-23 111-24
0O 0H0O OH 0 0NN 0' N 0-y N N 0 N" 'N N, N)NANCH 3 N' zN , N H N 0 NN 0 N,N~
FF F F sF s F s F . F F 11-101 11-102 11-103 1-0
OHO0 OHO0 OHO0 0 OHO0 0 0 N 0 N 0 N N")1 zz II 0 N N 00OH3 N N NHNN.A,~ NNN NN NH ~ l
F' F
F F NN N
11-106 11-107 11-108 11-105
OHO0 OHO0 OHO0 OHO0 N") N ~~~~ N")O-N--a N' N NN N OC2 CH2 00H 3
OH F OCH 3
FF Q /F -s ~ \ F" -S F F SF 11I-109 11-110 11-111 11-112
0, , 0 HC 0" 0 0,
0l- o N OA 0 NNo< 0 N- 0~k 0A- No
F sF S F S F 111-37 111-38 111-39 111-40
0 0 0-...0
N60 0 o-' 0 0., FCH F 0 N0 N 0 NN0 OCH3 N N N .NNN N N NNN
F sF sF F 111-41 111-42 111-43 111-44
0 0 H3 C, H3C~J H 3 CJ<A H 3 C J(IA -\O
00 00o 0 00-\
NT IIIA N-. N 0 N NN N 0 N' HoH 3CO
F F sF IF sF F s F' s
111-45 111-46 11147 111-48
0 0 0 0 -- \- Ao-\o 0C2HOAO_ 0 .o (H3C)2HC0,0 o - o ,-\ 0N,. NN NN NN~N N N NN.NA.0 NN)..o N. o N
F- FF F F \/ F-p F sF sF sF 111-49 111-50 111-51 111-52 0 0 0 0 -- OA -\o oC 2 HO0-\ 0 (H 3C) 2 HC0-\-- O 0 0 00
N NN.NAAN0 N oN N N'No A'0 N N' 40
FF F Fs S 111-53 111-54 F 11-5F 115
HC, 4 HCJ F 0 0 OO\ J: OO\o 0OF-~ H 3 CoA4 \ 00:4H 3 CJ<0-\0 F
0 ~J NN 0 N N N 0 NN
N ' N N 7 7 N 7 7 F (CS F( S F F F~s F~ 111-57 111-58 111-59 F 111-60
H 3 CSJ HC~j, F 0 3 ,0 0 o 0[0" OO-\o 0-\ 0 - N N 0-j- N 0 Io 'N NN 77F NF 'N lii N~Nz Nz N N
S S 111-61 111-62 111-63 111-64
0 0 0 0 OAO-\ o CH o-\0 (H 3C) 2 HC \0 0---- 0\
0 N0 Lz0 z'0N N N7
FF 1 F- S F - S F F F F 111-65 111-66 111-67 111-68
03 , 000 H 3 AC,-- 0A0- F HC A0\ 3 'A0
LZ N 1 N'N ' N Nl cl'N
111-69 111-70 111-71 111-72 0 0 H3 C0A --- 0 0 0 H00"p\ HO-P\ N 0 -P ZF 3 000"", H3C 0110,0 ~ F H60-oHlo-o0 H3A' -o"\-\ o 0 00 N- N N":4 0 0 - N ylANJ: 0 y) TNN
N N7 N N
F FF sF- Cs F F F F IV-i IV-2 IV-3 IV-4
0 HC0'( - 10 HP HOP FOR H- HCOA ~ -0 1/ H3 O-P\HCY HO \0N\ o ' H6 \0-\o ,F, I~\' \ F 0 Il N1: N HCOyO " ) oN 00 0 N N NN N 'IIN N 0N'
IV-5 cxO IV-6 N
>20o CS IV-7 CQO~ I
0 0 H 0O~ 0 HO O"NI. HO I \ H3CO HCOy 1-10 0 0N N N, 0~f 0 0 Ni' "fl-AN y 0NN 'N N.t Y NNN N.NY NN~ N)I
F F F IVF IV-12
0 00 0 1 H04H 3 O'~ 0H 3C00" ( o Hdo- '\o HO-" 03O 0--- 10, ' H 3O dP
' Od \\ 60o 0f H3O-P~ 1' 0 0H0 0 600 0 HO 0-l60\ N 0, N0N 1 L N N'N~ NL'' N4-" N 0
IV-13 IV-14 IV-15 IV-16
0 0 0 0 HO-P HO -P\O HO-P\ HO- *-O H\O\o 0 HO'-\ 0 0o HOl O'o 0oO~
01 Ni:) NN 01 NN F N1N~
F .- F'- \F -F
F sF sF sF IV-17 IV-18 IV-19 IV-20
0o H O -p HO-P HO-P\o H6'O-- HO-H H-P o 0 HO0- 0 0 0 0 HO\0--"'O ~ 0H 0" N Y''N -T-CH N0 N N 0 H0 N NJ 0N
F - F - F - F
IV-21 IV-22 IV-23IV2
0 H3 0( 0 0 HOH0 HO'R H3COAOH3CO O-P Hd OO\ 0 YO O-P ,\- H 3C0 0 0\ 0- HO 0\0 0 0 H 3 CO O0 0 0 Of Y0 0 01N 0 01
F F F F
F SF SFZ S1 F_ IV-25 IV-26 F IV-27 IV-28
0 00 HO' / HOP p HO O HO " HO-P0O 0 0 0 OCH3 H6 0'0 0 0 HO'\O O 0 0 0 OCH 3 O N 0 N N NH 0 N O
'N 'N
F F -F - F F F F F IV-29 IV-30 IV-31 IV-32
H 3C H 3 CN F H 3 CN H 3 CO N
111-0 111-71 111-72 0 N~r 1 NNoa NN ) ) N N N NN N,
S
111-69 111-70 111-71 111-72
37. A pharmaceutical composition containing the pyridone derivative represented by Formula (I) or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 36, wherein the pharmaceutical composition is an antiviral pharmaceutical composition further optionally comprising one or more therapeutic agents selected from the group consisting of a neuraminidase inhibitor, a nucleoside drug, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs.
38. The pharmaceutical composition according to claim 37, wherein the pharmaceutical composition is a pharmaceutical preparation selected from a tablet, a powder, a capsule, a granule, an oral liquid, an injection, a powder, a suppository, a pill, a cream, a paste, a gel, a pulvis, an inhalant, a suspension, a dry suspension, a patch, a lotion or a nano preparation.
39. Use of the pyridone derivative represented by Formula (I) or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 36, or a combination of one or more of the pharmaceutical composition according to claim 37 or 38 in the preparation of a drug for preventing and/or treating a viral infection disease, the viral infection disease is preferably an influenza type A viral infection disease and/or an influenza type B viral infection disease.
40. Use of the pyridone derivative represented by Formula (I) or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 36, or a combination of one or more of the pharmaceutical composition according to claim 37 or 38 in the preparation of an antiviral drug, the antiviral drug is preferably a drug or an agent inhibiting influenza cap-dependent endonuclease activities.
41. A method for preventing and/or treating a viral infection disease, wherein the method comprises administering to an animal or human in need of prevention and/or treatment an effective amount of the pyridone derivative represented by Formula (I) or the stereoisomer, the pharmaceutically acceptable salt, the solvate or the crystal thereof according to any one of claims 1 to 36, or a combination of one or more of the pharmaceutical composition according to claim 37 or 38.
42. The method according to claim 41, is characterized in that, the viral infection disease is an infectious disease caused by influenza type A and/or influenza type B.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810044308.4A CN110041327B (en) | 2018-01-17 | 2018-01-17 | Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament |
| CN201810044308.4 | 2018-01-17 | ||
| CN201811517425.4 | 2018-12-12 | ||
| CN201811517425.4A CN111303147B (en) | 2018-12-12 | 2018-12-12 | Pyridone derivatives, compositions thereof and use as anti-influenza virus medicaments |
| PCT/CN2019/071902 WO2019141179A1 (en) | 2018-01-17 | 2019-01-16 | Pyridone derivative, composition thereof and application thereof as anti-influenza drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019210414A1 true AU2019210414A1 (en) | 2020-09-03 |
| AU2019210414B2 AU2019210414B2 (en) | 2021-04-01 |
Family
ID=67301986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019210414A Active AU2019210414B2 (en) | 2018-01-17 | 2019-01-16 | Pyridone derivative, composition thereof and application thereof as anti-influenza drug |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11247993B2 (en) |
| EP (1) | EP3753936A4 (en) |
| JP (1) | JP7352297B2 (en) |
| KR (1) | KR102477187B1 (en) |
| CN (4) | CN110637016B (en) |
| AU (1) | AU2019210414B2 (en) |
| CA (1) | CA3088926A1 (en) |
| PH (1) | PH12020551264A1 (en) |
| SG (1) | SG11202011447UA (en) |
| WO (1) | WO2019141179A1 (en) |
| ZA (1) | ZA202007143B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2881776T3 (en) | 2016-03-08 | 2021-11-30 | Novartis Ag | Tricyclic compounds useful for treating orthomyxovirus infections |
| JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| MX2020003469A (en) | 2017-10-06 | 2020-08-03 | Shionogi & Co | Method for stereoselectively producing substituted polycyclic pyridone derivative. |
| PL3759113T3 (en) * | 2018-02-28 | 2025-01-20 | Novartis Ag | 10-(DI(PHENYL)METHYL)-4-HYDROXY-8,9,9A,10-TETRAHYDRO-7H-PYRROLLO[1',2':4,5]PYRAZINO[1,2-B]PYRIDAZINE-3,5-DIONE DERIVATIVES AND RELATED COMPOUNDS AS ORTHOMYXOVIRUS REPLICATION INHIBITORS FOR THE TREATMENT OF INFLUENZA |
| CN112118891B (en) * | 2019-04-01 | 2023-10-31 | 尼坎医疗公司 | Fused polycyclic pyridone compounds as inhibitors of influenza virus replication |
| CN111909174B (en) * | 2019-05-08 | 2022-01-21 | 江西彩石医药科技有限公司 | Crystal form of pyridone derivative, preparation method and application |
| CN112574170A (en) * | 2019-09-29 | 2021-03-30 | 江西东邦药业有限公司 | Dibenzo seven-membered ring derivative and preparation method and application thereof |
| WO2021129602A1 (en) * | 2019-12-23 | 2021-07-01 | 石家庄迪斯凯威医药科技有限公司 | Substituted polycyclic compound and pharmaceutical composition and use thereof |
| CN113045589B (en) * | 2019-12-27 | 2024-08-23 | 广东东阳光药业股份有限公司 | Influenza virus replication inhibitors and uses thereof |
| CN112898346B (en) * | 2020-01-23 | 2023-11-10 | 南京知和医药科技有限公司 | Water-soluble polycyclic compounds, pharmaceutical compositions and uses thereof |
| CN115244049A (en) * | 2020-03-06 | 2022-10-25 | 广东众生睿创生物科技有限公司 | A kind of pharmaceutical composition for treating influenza and preparation containing the pharmaceutical composition |
| CN111943879A (en) * | 2020-08-03 | 2020-11-17 | 南通大学 | A kind of (3S, 4R) 3-amino-4 (methoxymethyl) pyrrolidine-1-carboxylic acid tert-butyl ester and its synthesis method |
| CN113583022B (en) * | 2020-08-11 | 2025-03-18 | 石家庄迪斯凯威医药科技有限公司 | Polycyclic compounds and pharmaceutical compositions and uses thereof |
| CN115385932A (en) * | 2021-05-22 | 2022-11-25 | 江西彩石医药科技有限公司 | Intermediate of pyridone derivative and preparation method thereof |
| WO2024074080A1 (en) * | 2022-10-08 | 2024-04-11 | 石家庄迪斯凯威医药科技有限公司 | Anti-influenza virus derivative and use thereof |
| CN117003771B (en) * | 2022-11-09 | 2024-02-02 | 石家庄迪斯凯威医药科技有限公司 | Anti-influenza virus derivative and application thereof |
| CN116789556A (en) * | 2023-05-26 | 2023-09-22 | 康化（上海）新药研发有限公司 | A kind of preparation method containing cyclopropoxyethylamine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010147068A1 (en) | 2009-06-15 | 2010-12-23 | 塩野義製薬株式会社 | Substituted polycyclic carbamoylpyridone derivative |
| US8987441B2 (en) | 2010-09-24 | 2015-03-24 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
| UA121199C2 (en) * | 2013-09-12 | 2020-04-27 | Аліос Біофарма, Інк. | AZAPYRIDONE COMPOUNDS AND THEIR APPLICATIONS |
| ES2857906T3 (en) | 2015-04-28 | 2021-09-29 | Shionogi & Co | Influenza polycyclic pyridone derivative and prodrug thereof |
| JP5971830B1 (en) * | 2015-04-28 | 2016-08-17 | 塩野義製薬株式会社 | Substituted polycyclic pyridone derivatives and prodrugs thereof |
| SG11201804348SA (en) * | 2015-12-15 | 2018-06-28 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| JP6806413B2 (en) * | 2016-02-03 | 2021-01-06 | 塩野義製薬株式会社 | Polycyclic pyridone derivatives and their prodrugs |
| MA45939A (en) * | 2016-08-10 | 2019-06-19 | Shionogi & Co | SUBSTITUTE POLYCYCLIC PYRIDONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING A PROOF OF THE SAME |
| JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
-
2019
- 2019-01-16 SG SG11202011447UA patent/SG11202011447UA/en unknown
- 2019-01-16 CN CN201980000078.4A patent/CN110637016B/en active Active
- 2019-01-16 KR KR1020207023803A patent/KR102477187B1/en active Active
- 2019-01-16 CA CA3088926A patent/CA3088926A1/en active Pending
- 2019-01-16 CN CN202010817435.0A patent/CN111848616B/en active Active
- 2019-01-16 AU AU2019210414A patent/AU2019210414B2/en active Active
- 2019-01-16 CN CN202010817035.XA patent/CN111848614B/en active Active
- 2019-01-16 US US16/487,088 patent/US11247993B2/en active Active
- 2019-01-16 JP JP2020560532A patent/JP7352297B2/en active Active
- 2019-01-16 CN CN202010817434.6A patent/CN111848615B/en active Active
- 2019-01-16 EP EP19741336.2A patent/EP3753936A4/en active Pending
- 2019-01-16 WO PCT/CN2019/071902 patent/WO2019141179A1/en unknown
-
2020
- 2020-08-17 PH PH12020551264A patent/PH12020551264A1/en unknown
- 2020-11-16 ZA ZA2020/07143A patent/ZA202007143B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111848615B (en) | 2022-05-17 |
| CN110637016B (en) | 2020-08-18 |
| CA3088926A1 (en) | 2019-07-25 |
| CN110637016A (en) | 2019-12-31 |
| US20190367517A1 (en) | 2019-12-05 |
| EP3753936A4 (en) | 2022-03-23 |
| CN111848615A (en) | 2020-10-30 |
| AU2019210414B2 (en) | 2021-04-01 |
| CN111848616A (en) | 2020-10-30 |
| JP7352297B2 (en) | 2023-09-28 |
| WO2019141179A1 (en) | 2019-07-25 |
| SG11202011447UA (en) | 2020-12-30 |
| ZA202007143B (en) | 2022-04-28 |
| CN111848616B (en) | 2021-11-23 |
| JP2021511374A (en) | 2021-05-06 |
| PH12020551264A1 (en) | 2021-05-31 |
| KR20200118062A (en) | 2020-10-14 |
| EP3753936A1 (en) | 2020-12-23 |
| CN111848614A (en) | 2020-10-30 |
| CN111848614B (en) | 2021-11-23 |
| US11247993B2 (en) | 2022-02-15 |
| KR102477187B1 (en) | 2022-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019210414A1 (en) | Pyridone derivative, composition thereof and application thereof as anti-influenza drug | |
| CA2930209C (en) | Tetrahydroimidazopyridine derivatives as modulators of tnf activity | |
| CA2930754C (en) | Pyrazolopyridine derivatives as modulators of tnf activity | |
| AU2016256125B9 (en) | Substituted polycyclic pyridone derivative and prodrug thereof | |
| CN110041327B (en) | Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament | |
| CA3008607A1 (en) | A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug | |
| CA2572208C (en) | 3-carbamoyl-2-pyridone derivative | |
| CA2690913C (en) | Ire-1.alpha. inhibitors | |
| CA2931022C (en) | Imidazopyridine derivatives as modulators of tnf activity | |
| WO2012119941A1 (en) | Peptidyl nitrilcompounds as peptidase inhibitors | |
| US9440954B2 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| RU2656209C2 (en) | Therapeutically active derivatives of oxazoline | |
| AU2014260605A1 (en) | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | |
| KR102630010B1 (en) | Tricyclic heterocyclic compounds useful as inhibitors of TNF | |
| CA2930866A1 (en) | Imidazotriazine derivatives as modulators of tnf activity | |
| CN111303147B (en) | Pyridone derivatives, compositions thereof and use as anti-influenza virus medicaments | |
| CA3116830A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| CA2930345A1 (en) | Triazolopyridazine derivatives as modulators of tnf activity | |
| TW460441B (en) | Matrix metalloproteinase inhibitors | |
| WO2010020663A1 (en) | New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents | |
| US8980938B2 (en) | CXCR2 inhibitors | |
| HK40032909A (en) | Pyridone derivative, composition thereof and application thereof as anti-influenza drug | |
| EA045400B1 (en) | PYRIDONE DERIVATIVE, ITS COMPOSITION AND APPLICATION AS AN ANTI-VIRAL MEDICINE | |
| CA3238521A1 (en) | Heterocyclic amides and methods of using the same | |
| MXPA02002623A (en) | Aryl sulfonamide substituted benzimidazol derivatives and use of said as tryptase inhibitors. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |